L Number	Hits	Search Text	DB	Time stamp
1	99	quercetin near3 glycosid$	USPAT; US-PGPUB; DERWENT	2003/04/17 10:23
14	119022	osteopor$ or bone	USPAT; US-PGPUB; DERWENT	2003/04/17 10:29
18	2	(quercetin near3 glycosid$) same (osteopor$ or bone)	USPAT; US-PGPUB; DERWENT	2003/04/17 10:45
22	2	(quercetin near3 glycosid$) same cyclodextrin	USPAT; US-PGPUB; DERWENT	2003/04/17 10:45

Welcome to STN International! Enter x:x

LOGINID:ssspta1803kkf

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Mar 24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS 32	Apr 11	Display formats in DGENE enhanced
NEWS 33	Apr 14	MEDLINE Reload

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:51:36 ON 17 APR 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:51:45 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8
DICTIONARY FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e quercetin/cn

E1	1	QUERCETAGETIN, 7-.BETA.-D-GLUCOPYRANOSIDE/CN
E2	1	QUERCETAGITRIN/CN
E3	1 -->	QUERCETIN/CN
E4	1	QUERCETIN 1,2-NAPHTHOQUINONEDIAZIDO-5-SULFONATE/CN
E5	1	QUERCETIN 2,3-DIOXYGENASE/CN
E6	1	QUERCETIN 3',4',5,7-TETRAMETHYL ETHER/CN
E7	1	QUERCETIN 3',4',7-TRIMETHYL ETHER/CN
E8	1	QUERCETIN 3',4'-DIMETHYL ETHER/CN
E9	1	QUERCETIN 3',7-DIMETHYL ETHER/CN
E10	1	QUERCETIN 3',7-DISULFATE/CN
E11	1	QUERCETIN 3'-GLUCOSIDE/CN
E12	1	QUERCETIN 3'-METHYL ETHER/CN

=> s e3

L1	1	QUERCETIN/CN

=> d str

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 117-39-5 REGISTRY
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Flavone, 3,3',4',5,7-pentahydroxy- (7CI, 8CI)
CN Flavone, 3,4',5,5',7-pentahydroxy- (6CI)
OTHER NAMES:
CN 3,3',4',5,7-Pentahydroxyflavone
CN 3,5,7,3',4'-Pentahydroxyflavone
CN C.I. 75670
CN C.I. Natural Yellow 10
CN Cyanidelonon 1522
CN Meletin
CN **Quercetin**
CN Quercetine
CN Quercetol
CN Quercitin
CN Quertin
CN Quertine
CN Sophoretin
CN Xanthaurine
FS 3D CONCORD
DR 73123-10-1, 74893-81-5
MF C15 H10 O7
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
            8006 REFERENCES IN FILE CA (1962 TO DATE)
             602 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            8038 REFERENCES IN FILE CAPLUS (1962 TO DATE)
               2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


=> e quercitin/cn
E1            1     QUERCINIC ACID METHYL ESTER ACETATE/CN
E2            1     QUERCINITOL/CN
E3            1 --> QUERCITIN/CN
E4            1     QUERCITIN 3',4',7-TRIMETHYL ETHER 3-O-.ALPHA.-L-RHAMNOPYRANO
                    SIDE/CN
E5            1     QUERCITOL/CN
E6            1     QUERCITOL 3-RHAMNOSIDE/CN
E7            1     QUERCITOL, (+)-PROTO-/CN
E8            1     QUERCITOL, (-)-PROTO-/CN
E9            1     QUERCITOL, (-)-VIBO-/CN
E10           1     QUERCITOL, 3-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSIDE)/CN
E11           1     QUERCITOL, CIS-/CN
E12           1     QUERCITOL, EPI-/CN

=> s e3
L2            1 QUERCITIN/CN

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   117-39-5  REGISTRY
CN   4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI)
     (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Flavone, 3,3',4',5,7-pentahydroxy- (7CI, 8CI)
CN   Flavone, 3,4',5,5',7-pentahydroxy- (6CI)
OTHER NAMES:
CN   3,3',4',5,7-Pentahydroxyflavone
CN   3,5,7,3',4'-Pentahydroxyflavone
CN   C.I. 75670
CN   C.I. Natural Yellow 10
CN   Cyanidelonon 1522
CN   Meletin
CN   Quercetin
CN   Quercetine
CN   Quercetol
CN   Quercitin
CN   Quertin
CN   Quertine
CN   Sophoretin
CN   Xanthaurine
FS   3D CONCORD
DR   73123-10-1, 74893-81-5
MF   C15 H10 O7
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
       CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU,
       DETHERM*, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT,
       IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR,
       PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, USPAT2,
       USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8006 REFERENCES IN FILE CA (1962 TO DATE)
602 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8038 REFERENCES IN FILE CAPLUS (1962 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e isorhamnetin/cn
E1            1     ISOREYNOSIN, DIHYDRO-/CN
E2            1     ISOREZ 7/CN
E3            1 --> ISORHAMNETIN/CN
E4            1     ISORHAMNETIN 3,4'-O-DIGLUCOSIDE/CN
E5            1     ISORHAMNETIN 3,7,4'-TRISULFATE/CN
E6            1     ISORHAMNETIN 3,7-DIMETHYL ETHER/CN
E7            1     ISORHAMNETIN 3,7-DISULFATE/CN
E8            1     ISORHAMNETIN 3,7-O-DIGLUCOSIDE/CN
E9            1     ISORHAMNETIN 3-.ALPHA.-L-ARABINOFURANOSIDE/CN
E10           1     ISORHAMNETIN 3-.ALPHA.-L-ARABINOSIDE/CN
E11           1     ISORHAMNETIN 3-.ALPHA.-L-RHAMNOFURANOSIDE/CN
E12           1     ISORHAMNETIN 3-.BETA.-D-GALACTOPYRANOSIDE/CN

=> s e3
L3            1 ISORHAMNETIN/CN

=> d

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   480-19-3  REGISTRY
CN   4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Flavone, 3,4',5,7-tetrahydroxy-3'-methoxy- (8CI)
CN   Isorhamnetin (6CI)
OTHER NAMES:
CN   3'-Methoxyquercetin
CN   3'-Methylquercetin
CN   3'-O-Methylquercetin
CN   3,4',5,7-Tetrahydroxy-3'-methoxyflavone
CN   C.I. 75680
CN   Isorhamnetol
CN   Quercetin 3'-methyl ether
FS   3D CONCORD
MF   C16 H12 O7
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS,
       CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT,
       PIRA, RTECS*, SPECINFO, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

910 REFERENCES IN FILE CA (1962 TO DATE)
80 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
912 REFERENCES IN FILE CAPLUS (1962 TO DATE)
41 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e quercimeritrin/cn
E1            1     QUERCILICOSIDE A/CN
E2            1     QUERCIMELIN/CN
E3            1 --> QUERCIMERITRIN/CN
E4            1     QUERCIMERITRIN TETRAMETHYL ETHER/CN
E5            1     QUERCIMERITRIN, 2'',3'',4'',6''-TETRAACETATE 3,3',4',5-TETRA
                    BENZOATE/CN
E6            1     QUERCIMERITRIN, 3,3',4',5-TETRA-O-METHYL-/CN
E7            1     QUERCIMERITRIN, OCTAACETATE/CN
E8            1     QUERCIMERITRIN, TRIHYDRATE/CN
E9            1     QUERCIMERITROSIDE/CN
E10           1     QUERCINIC ACID/CN
E11           1     QUERCINIC ACID ACETATE/CN
E12           1     QUERCINIC ACID B/CN

=> s e3
L4            1 QUERCIMERITRIN/CN

=> d

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   491-50-9  REGISTRY
CN   4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-
     glucopyranosyloxy)-3,5-dihydroxy- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Quercimeritrin (6CI, 7CI, 8CI)
OTHER NAMES:
CN   C.I. 75710
CN   Quercetin 7-.beta.-D-glucopyranoside
CN   Quercetin 7-O-.beta.-D-glucopyranoside
CN   Quercetin 7-O-.beta.-D-glucoside
CN   Quercimeritroside
FS   STEREOSEARCH
DR   133-97-1, 1331-97-1, 30113-30-5
MF   C21 H20 O12
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
       CAOLD, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, IPA, MEDLINE,
       MRCK*, NAPRALERT, RTECS*, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

317 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
317 REFERENCES IN FILE CAPLUS (1962 TO DATE)
24 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e rhamnetin/cn
E1            1     RHAMNEPALIN B/CN
E2            1     RHAMNEPALIN C/CN
E3            1 --> RHAMNETIN/CN
E4            1     RHAMNETIN 3-ARABINOSIDE/CN
E5            1     RHAMNETIN 3-GALACTOSIDE/CN
E6            1     RHAMNETIN 3-GLUCOSIDE/CN
E7            1     RHAMNETIN 3-O-.BETA.-D-GALACTOPYRANOSIDE/CN
E8            1     RHAMNETIN 3-O-.BETA.-D-GLUCOPYRANOSIDE/CN
E9            1     RHAMNETIN 3-O-.BETA.-D-RHAMNINOSIDE/CN
E10           1     RHAMNETIN 3-O-.BETA.-GLUCOPYRANOSIDE/CN
E11           1     RHAMNETIN 3-O-.BETA.-NEOHESPERIDOSIDE/CN
E12           1     RHAMNETIN 3-O-GLUCOSIDE/CN

=> s e3
L5            1 RHAMNETIN/CN

=> d

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   90-19-7  REGISTRY
CN   4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxy-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Flavone, 3,3',4',5-tetrahydroxy-7-methoxy- (7CI, 8CI)
CN   Rhamnetin (6CI)
OTHER NAMES:
CN   .beta.-Rhamnocitrin
CN   3,3',4',5-Tetrahydroxy-7-methoxyflavone
CN   3,5,3',4'-Tetrahydroxy-7-methoxyflavone
CN   7-Methoxyquercetin
CN   7-Methylquercetin
CN   7-O-Methylquercetin
CN   C.I. 75690
CN   LY 805921
CN   Quercetin 7-methyl ether
FS   3D CONCORD
MF   C16 H12 O7
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
       CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA,
       MEDLINE, MRCK*, NAPRALERT, RTECS*, SPECINFO, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)
```

Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

400 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
401 REFERENCES IN FILE CAPLUS (1962 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e spireaoside/cn
E1            1     SPIRAZIDINE/CN
E2            1     SPIRAZINE/CN
E3            0 --> SPIREAOSIDE/CN
E4            1     SPIREDINE/CN
E5            1     SPIREF/CN
E6            1     SPIREL/CN
E7            1     SPIRENDOLOL/CN
E8            1     SPIREOSIDE/CN
E9            1     SPIRESIS/CN
E10           1     SPIRETIC/CN
E11           1     SPIRGETINE/CN
E12           1     SPIRIDON/CN

=> e quercetin-7-o-/cn
E1            1     QUERCETIN-7,4'-DISULFATE/CN
E2            1     QUERCETIN-7-NEOHESPERIDOSIDE/CN
E3            0 --> QUERCETIN-7-O-/CN
E4            1     QUERCETIN-7-O-GALACTOSIDE/CN
E5            1     QUERCETIN-8,5'-DISULFONIC ACID/CN
E6            1     QUERCETIN-8,5'-DISULFONIC ACID DISODIUM SALT/CN
E7            1     QUERCETIN-8-SULFONIC ACID/CN
E8            1     QUERCETIN-CYPROCONAZOLE MIXT./CN
E9            1     QUERCETIN-GLYCYRRHIZIN MIXT./CN
E10           1     QUERCETIN-L-DOPA COPOLYMER/CN
E11           1     QUERCETIN-PROPICONAZOLE MIXT./CN
E12           1     QUERCETINASE/CN

=> s e4
L6            1 QUERCETIN-7-O-GALACTOSIDE/CN

=> d

L6   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN   59985-52-3  REGISTRY
CN   4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-
     galactopyranosyloxy)-3,5-dihydroxy- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Quercetin, 7-.beta.-D-galactopyranoside (6CI)
OTHER NAMES:
CN   Coptiside II
```

CN Quercetin 7-O-.beta.-D-galactopyranoside
CN Quercetin 7-O-.beta.-D-galactoside
CN **Quercetin-7-O-galactoside**
FS STEREOSEARCH
MF C21 H20 O12
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, NAPRALERT
        (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> e quercetin-3/cn
E1            1     QUERCETIN, TRIGLUCOSIDE/CN
E2            1     QUERCETIN-2-14C/CN
E3            0 --> QUERCETIN-3/CN
E4            1     QUERCETIN-3',4'-DISULFATE/CN
E5            1     QUERCETIN-3,7,3'-TRIMETHYL ETHER/CN
E6            1     QUERCETIN-3,7-O-.BETA.-DIGLUCOPYRANOSIDE/CN
E7            1     QUERCETIN-3-(O-ACETYL)-.BETA.-D-GLUCOPYRANOSIDE/CN
E8            1     QUERCETIN-3-(O-MALONYL)-.BETA.-D-GLUCOSIDE/CN
E9            1     QUERCETIN-3-.ALPHA.-L-RHAMNOPYRANOSIDE-7-.BETA.-D-GLUCOPYRAN
                    OSIDE-DECAACETATE/CN
E10           1     QUERCETIN-3-.BETA.-D-GALACTOPYRANOSYL-6-.ALPHA.-L-ARABINOPYR
                    ANOSIDE/CN
E11           1     QUERCETIN-3-.BETA.-D-GLUCOFURANOSYL-6-.BETA.-L-RHAMNOPYRANOS
                    IDE/CN
E12           1     QUERCETIN-3-.BETA.-D-GLUCOPYRANOSYL-(1.FWDARW.4)-.ALPHA.-L-R
                    HAMNOPYRANOSIDE/CN

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               40.63      40.84

FILE 'CAPLUS' ENTERED AT 10:58:24 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 16 Apr 2003 (20030416/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> e kim c?/au and ha h?/au and song k?/au
E1          220      KIM C W/AU
E2          164      KIM C Y/AU
E3            0 --> KIM C?/AU AND HA H?/AU AND SONG K?/AU
E4            1      KIM CADENCE/AU
E5            1      KIM CAIUS/AU
E6            1      KIM CALVIN H/AU
E7            6      KIM CALVIN HYUNGCHAN/AU
E8            1      KIM CARIN J/AU
E9            1      KIM CARL S/AU
E10           1      KIM CAROL A/AU
E11          11      KIM CAROL H/AU
E12           1      KIM CAROL H Y/AU

=> e kim c?/au and ha h?/au and song k?/au
E1          220      KIM C W/AU
E2          164      KIM C Y/AU
E3            0 --> KIM C?/AU AND HA H?/AU AND SONG K?/AU
E4            1      KIM CADENCE/AU
E5            1      KIM CAIUS/AU
E6            1      KIM CALVIN H/AU
E7            6      KIM CALVIN HYUNGCHAN/AU
E8            1      KIM CARIN J/AU
E9            1      KIM CARL S/AU
E10           1      KIM CAROL A/AU
E11          11      KIM CAROL H/AU
E12           1      KIM CAROL H Y/AU

=> s kim c?/au and ha h?/au and song k?/au
         10425 KIM C?/AU
           537 HA H?/AU
          1743 SONG K?/AU
L7           1 KIM C?/AU AND HA H?/AU AND SONG K?/AU

=> d

L7   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:171679  CAPLUS
DN   136:221722
TI   Anti-osteoporosis compositions containing quercetin derivatives
IN   Kim, Chung-sook; Ha, Hye-kyung; Song, Kye-yong
PA   Korea Institute of Oriental Medicine, S. Korea
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
PI   WO 2002017909       A1   20020307      WO 2001-KR368    20010309
```

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001041236     A5   20020313       AU 2001-41236    20010309
     US 2002165169     A1   20021107       US 2002-70047    20020222
PRAI KR 2000-46916     A    20000814
     WO 2001-KR368     W    20010309
OS   MARPAT 136:221722
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> transfer
ENTER L# (L7) OR ?:
ENTER L# (L7) OR ?:l7
ENTER ANSWER NUMBERS, RANGES (1-), OR ?:?
To specify answer numbers, enter:

   an answer number, e.g., 10
   several answer numbers, e.g., 3,7,10
   a range of answer numbers, e.g., 5-10
   or a combination of these, e.g., 3,7,9-10,15

The default is to use all answers (1-) in the answer set.
ENTER ANSWER NUMBERS, RANGES (1-), OR ?:1-
ENTER DISPLAY FIELDS (TI) OR ?:?
Enter the display field from which the data is to be extracted.
ENTER DISPLAY FIELDS (TI) OR ?:rn
L8          TRANSFER L7 1- RN :      80 TERMS
L9      707998 L8

=> s l9 and (bone or bony or osteo? or ossi? or osseo?)
         142748 BONE
          18971 BONES
         148175 BONE
                (BONE OR BONES)
           1768 BONY
          46611 OSTEO?
           3079 OSSI?
           1652 OSSEO?
L10       21359 L9 AND (BONE OR BONY OR OSTEO? OR OSSI? OR OSSEO?)

=> d 1-10 scan
'1-10' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

L10   21359 ANSWERS   CAPLUS  COPYRIGHT 2003 ACS
IC    ICM  C07C057-40
      ICS  C07C057-44; C07C069-736; C07C229-34; C07C233-47; C07C233-55;
           C07C233-65; C07C233-81; C07C233-87; C07C235-38; C07C235-42;
           C07C235-46; C07C235-48; C07C235-54; C07C235-56; C07C237-30;
           C07C239-18; C07C255-37; C07C255-55; C07C255-57
CC    28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
      Section cross-reference(s): 25, 27, 63
TI    Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic
      acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
ST    heterocyclyl substituted benzoic acid prepn antagonist prostaglandin E2
      receptor; alkanoic acid heterocyclyl substituted prepn antagonist
      prostaglandin E2 receptor; prostaglandin E2 receptor subtype EP3 EP4
```

antagonist; pyrazolylmethylcinnamic acid prepn antagonist prostaglandin E2 receptor; phenylpropanoic acid prepn antagonist prostaglandin E2 receptor; phenylpropenoic acid prepn treatment pain; phenylpropanamide prepn treatment allodynia; phenylpropenamide prepn treatment hyperalgesia; oxoisoindolinylacetic acid prepn treatment pruritus itching; benzylbenzoic acid prepn treatment urticaria; benzylaminoacetic acid prepn treatment atopic dermatitis; pyrazolylmethylbenzoic acid prepn treatment contact dermatitis; benzoylaminoacetic acid prepn treatment Urushi dermatitis; pyrazolylmethylphenylpropenoic acid prepn treatment allergic conjunctivitis; pyrazolylmethylpropanoic acid prepn treatment symptoms during dialysis; pyridinyloxyphenylpropanoic acid prepn treatment asthma; phenoxyacetic acid prepn treatment rhinitis; phenylbutanoic acid prepn treatment allergic rhinitis; nasal congestion treatment benzylbenzoic acid prepn; pyrazolylmethylpropanamide prepn treatment sneeze; piperazinylmethylphenylpropanamide prepn treatment psoriasis; morpholinylmethylphenylpropanamide prepn treatment pollakiuria; pyridinyloxyphenylpropanamide prepn treatment urination disorder; pyrazolylmethylpropenamide prepn treatment ejaculation semination disorder; oxoimidazolidinylmethylphenylpropanamide prepn treatment fever pyrexia; oxopyrrolidinylmethylphenylpropenamide prepn treatment systemic inflammation reaction; thiophenylmethylphenylpropenamide prepn treatment learning disorder; pyrazolylmethylphenylaminoacetamide prepn treatment Alzheimer disease; thiazolylaminomethylphenylpropanamide prepn treatment neovascularization; pyrazolylmethylphenoxyacetamide prepn treatment cancer formation; thiophenylpropenamide prepn treatment cancer proliferation; cancer metastasis organ **bone** treatment pyrazolylmethylphenylaminoacetamide prepn; hypercalcemia accompanied cancer metastasis **bone** treatment phenylpropenoic acid prepn

IT Intestine, disease
(Crohn's; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Blood vessel, disease
(Kawasaki; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Dermatitis
(Urushi (Japanese lacquer tree); prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Hepatitis
(acute; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aids for decreasing or removing steroid drugs; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Eye, disease
(allergic conjunctivitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Nose
(allergic rhinitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Pain
Skin, disease
(allodynia; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Intestine
(anus, anal fistula; prepn. of aryl or heterocyclyl-substituted benzoic

acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Ulcer
(assocd. with circulation disorders; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Atherosclerosis
(atheroma; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Dermatitis
(atopic; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Bile
(biliary excretion disorder; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Headache
(chronic; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Nose
(congestion; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Intestine, disease
(constipation; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Dermatitis
(contact; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Mental disorder
(dementia, vascular; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Mental disorder
(depression; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Blood
(disease, blood electrolyte disorder; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Vein
(disease, venous failure; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Periodontium
(disease; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Circulation
Immunity
Learning
Micturition
Reproduction, animal
(disorder; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Sexual behavior
(ejaculation, semination disorder; prepn. of aryl or

heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Uterus, disease
(endometriosis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Menstruation
(excessive; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Heart, disease
Kidney, disease
(failure; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Neoplasm
(formation or proliferation inhibitors; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Gingiva
(gingivitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Uterus
(gland, myopathy; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Pain
(hyperalgesia; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Abortion
(imminent or threatened; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Brain, disease
Heart, disease
(infarction; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Intestine, disease
(irritable bowel syndrome; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Brain, disease
(ischemia, transient; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Heart, disease
(ischemia; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Neoplasm
(metastasis, inhibitors of cancer metastasis to organs and **bone** ; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Skin, disease
(moth-patch; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Angiogenesis
(neovascularization; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2

(PEG2) receptors as therapeutic agents)
IT Kidney, disease
(nephritis, acute or chronic; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Nerve
(neuron, cell death; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Artery, disease
(patent ductus arteriosus, neonatal; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Periodontium
(periodontitis, pyorrhea alveolaris; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Ovarian cycle
(premenstrual syndrome; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Alzheimer's disease
Analgesics
Anti-Alzheimer's agents
Antiarteriosclerotics
Antiasthmatics
Anticoagulants
Antidepressants
Antihypertensives
Antipyretics
Antitumor agents
Anxiety
Anxiolytics
Arteriosclerosis
Asthma
Bone, disease
Burn
Calculi, biliary
Diabetes insipidus
Diarrhea
Dysmenorrhea
Edema
Embolism
Fever and Hyperthermia
Hypertension
Immunomodulators
Kidney, disease
Leucoma
Liver, disease
Lung, disease
Mental retardation
Multiple organ failure
Nerve, disease
Pain
Pruritus
Psoriasis
Stress, animal
Thrombus
Transplant and Transplantation
Urticaria
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)
IT Carboxylic acids, preparation

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Medicine
(psychol., psychophysiol. disorders; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Erythema
(rash; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(redn. of rebound after using steroid drugs; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Eye, disease
(retinopathy; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Nose
(rhinitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Breathing (animal)
(sneezing; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Steroids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(steroid burn; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Burn
(steroid or heat; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Dialysis
(symptoms during dialysis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Anti-inflammatory agents
Inflammation
(systemic inflammation reaction; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Granuloma
(systemic; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Prostanoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type EP, subtype EP3 and/or subtype EP4; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Intestine, disease
(ulcerative colitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Antiulcer agents
(ulcers assocd. with circulation disorders; prepn. of aryl or

heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Urinary tract
(urinary frequency, increased urinary frequency; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Vein
(varicose vein, varicosis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT Blood vessel, disease
(vasculitis; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hypercalcemia, accompanied by cancer metastasis to **bone**; prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499143-47-4P 499143-48-5P 499143-50-9P 499143-51-0P 499143-52-1P
499143-53-2P 499143-54-3P 499143-55-4P 499143-56-5P 499143-57-6P
499143-58-7P 499143-59-8P 499143-60-1P 499143-61-2P 499145-83-4P
499145-84-5P 499145-85-6P 499145-86-7P 499145-87-8P 499145-88-9P
499145-89-0P 499145-90-3P 499145-91-4P 499145-92-5P 499145-93-6P
499145-94-7P 499145-95-8P 499145-96-9P 499145-97-0P 499145-98-1P
499145-99-2P 499146-00-8P 499146-01-9P 499146-02-0P 499146-03-1P
499146-04-2P 499146-05-3P 499146-06-4P 499146-07-5P 499146-08-6P
499146-09-7P 499146-10-0P 499146-11-1P 499146-12-2P 499146-13-3P
499146-14-4P 499146-15-5P 499146-16-6P 499146-17-7P 499146-18-8P
499146-19-9P 499146-20-2P 499146-21-3P 499146-22-4P 499146-23-5P
499146-24-6P 499146-25-7P 499146-26-8P 499146-27-9P 499146-28-0P
499146-29-1P 499146-30-4P 499146-31-5P 499146-32-6P 499146-33-7P
499146-34-8P 499146-35-9P 499146-36-0P 499146-37-1P 499146-38-2P
499146-39-3P 499146-40-6P 499146-41-7P 499146-42-8P 499146-43-9P
499146-44-0P 499146-45-1P 499146-46-2P 499146-47-3P 499146-48-4P
499146-49-5P 499146-50-8P 499146-51-9P 499146-52-0P 499146-53-1P
499146-54-2P 499146-55-3P 499146-56-4P 499146-57-5P 499146-58-6P
499146-59-7P 499146-60-0P 499146-61-1P 499146-62-2P 499146-63-3P
499154-19-7P 499154-26-6P 499154-34-6P 499154-39-1P 499154-41-5P
499157-08-3P 499159-57-8P 499159-58-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499143-62-3P 499143-63-4P 499143-64-5P 499143-65-6P 499143-66-7P
499143-67-8P 499143-68-9P 499143-69-0P 499143-70-3P 499143-71-4P
499143-72-5P 499143-73-6P 499143-74-7P 499143-75-8P 499143-76-9P
499143-77-0P 499143-78-1P 499143-79-2P 499143-80-5P 499143-81-6P
499143-82-7P 499143-83-8P 499143-84-9P 499143-85-0P 499143-86-1P
499143-87-2P 499143-88-3P 499143-89-4P 499143-90-7P 499143-91-8P
499143-92-9P 499143-93-0P 499143-94-1P 499143-95-2P 499143-96-3P
499143-97-4P 499143-98-5P 499143-99-6P 499144-00-2P 499144-01-3P
499144-02-4P 499144-03-5P 499144-04-6P 499144-05-7P 499144-06-8P
499144-07-9P 499144-08-0P 499144-09-1P 499144-10-4P 499144-11-5P
499144-12-6P 499144-13-7P 499144-14-8P 499144-15-9P 499144-16-0P
499144-17-1P 499144-18-2P 499144-19-3P 499144-20-6P 499144-22-8P
499144-23-9P 499144-25-1P 499144-26-2P 499144-27-3P 499144-28-4P
499144-29-5P 499144-31-9P 499144-32-0P 499144-33-1P 499144-34-2P
499144-35-3P 499144-36-4P 499144-38-6P 499144-39-7P 499144-40-0P
499144-41-1P 499144-42-2P 499144-43-3P 499144-44-4P 499144-45-5P
499144-46-6P 499144-47-7P 499144-48-8P 499144-49-9P 499144-50-2P

499144-51-3P 499144-52-4P 499144-53-5P 499144-54-6P 499144-55-7P
499144-56-8P 499144-57-9P 499144-58-0P 499144-59-1P 499144-60-4P
499144-61-5P 499144-62-6P 499144-63-7P 499144-64-8P 499144-65-9P
499144-66-0P 499144-67-1P 499144-68-2P 499144-69-3P 499144-70-6P
499144-71-7P 499144-72-8P 499144-73-9P 499144-74-0P 499144-75-1P
499144-76-2P 499144-77-3P 499144-78-4P 499144-79-5P 499144-80-8P
499144-81-9P 499144-82-0P 499144-83-1P 499144-85-3P 499144-87-5P
499144-89-7P 499144-91-1P 499144-93-3P 499144-95-5P 499144-97-7P
499144-99-9P 499145-00-5P 499145-01-6P 499145-02-7P 499145-03-8P
499145-04-9P 499145-06-1P 499145-07-2P 499145-08-3P 499145-09-4P
499145-10-7P 499145-11-8P 499145-12-9P 499145-13-0P 499145-14-1P
499145-15-2P 499145-16-3P 499145-17-4P 499145-18-5P 499145-19-6P
499145-20-9P 499145-21-0P 499145-22-1P 499145-23-2P 499145-24-3P
499145-25-4P 499145-26-5P 499145-27-6P 499145-28-7P 499145-29-8P
499145-30-1P 499145-31-2P 499145-32-3P 499145-33-4P 499145-34-5P
499145-35-6P 499145-36-7P 499145-37-8P 499145-38-9P 499145-39-0P
499145-40-3P 499145-41-4P 499145-42-5P 499145-43-6P 499145-44-7P
499145-45-8P 499145-46-9P 499145-47-0P 499145-48-1P 499145-49-2P
499145-50-5P 499145-51-6P 499145-52-7P 499145-53-8P 499145-54-9P
499145-55-0P 499145-56-1P 499145-57-2P 499145-58-3P 499145-59-4P
499145-60-7P 499145-61-8P 499145-62-9P 499145-63-0P 499145-64-1P
499145-65-2P 499145-66-3P 499145-67-4P 499145-68-5P 499145-69-6P
499145-70-9P 499145-71-0P 499145-72-1P 499145-73-2P 499145-74-3P
499145-75-4P 499145-76-5P 499145-77-6P 499145-78-7P 499145-79-8P
499145-80-1P 499145-81-2P 499145-82-3P 499146-64-4P 499146-65-5P
499146-66-6P 499146-67-7P 499146-68-8P 499146-69-9P 499146-70-2P
499146-71-3P 499146-72-4P 499146-73-5P 499146-74-6P 499146-75-7P
499146-76-8P 499146-77-9P 499146-78-0P 499146-79-1P 499146-80-4P
499146-81-5P 499146-82-6P 499146-83-7P 499146-84-8P 499146-85-9P
499146-86-0P 499146-87-1P 499146-88-2P 499146-89-3P 499146-90-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499146-91-7P 499146-92-8P 499146-93-9P 499146-94-0P 499146-95-1P
499146-96-2P 499146-97-3P 499146-98-4P 499146-99-5P 499147-00-1P
499147-01-2P 499147-02-3P 499147-03-4P 499147-04-5P 499147-05-6P
499147-06-7P 499147-07-8P 499147-08-9P 499147-09-0P 499147-10-3P
499147-11-4P 499147-12-5P 499147-13-6P 499147-14-7P 499147-15-8P
499147-16-9P 499147-17-0P 499147-18-1P 499147-19-2P 499147-20-5P
499147-21-6P 499147-22-7P 499147-23-8P 499147-24-9P 499147-25-0P
499147-26-1P 499147-27-2P 499147-28-3P 499147-29-4P 499147-30-7P
499147-31-8P 499147-32-9P 499147-33-0P 499147-34-1P 499147-35-2P
499147-36-3P 499147-37-4P 499147-38-5P 499147-39-6P 499147-40-9P
499147-41-0P 499147-42-1P 499147-43-2P 499147-44-3P 499147-45-4P
499147-46-5P 499147-47-6P 499147-48-7P 499147-49-8P 499147-50-1P
499147-51-2P 499147-52-3P 499147-54-5P 499147-56-7P 499147-58-9P
499147-59-0P 499147-61-4P 499147-63-6P 499147-65-8P 499147-67-0P
499147-68-1P 499147-69-2P 499147-70-5P 499147-71-6P 499147-72-7P
499147-73-8P 499147-74-9P 499147-75-0P 499147-76-1P 499147-77-2P
499147-78-3P 499147-79-4P 499147-80-7P 499147-81-8P 499147-82-9P
499147-83-0P 499147-84-1P 499147-85-2P 499147-86-3P 499147-87-4P
499147-88-5P 499147-89-6P 499147-90-9P 499147-91-0P 499147-92-1P
499147-93-2P 499147-94-3P 499147-95-4P 499147-96-5P 499147-97-6P
499147-98-7P 499147-99-8P 499148-00-4P 499148-01-5P 499148-02-6P
499148-03-7P 499148-04-8P 499148-05-9P 499148-06-0P 499148-07-1P
499148-08-2P 499148-09-3P 499148-10-6P 499148-11-7P 499148-12-8P
499148-13-9P 499148-14-0P 499148-15-1P 499148-16-2P 499148-17-3P
499148-18-4P 499148-19-5P 499148-20-8P 499148-21-9P 499148-22-0P
499148-23-1P 499148-24-2P 499148-25-3P 499148-26-4P 499148-27-5P
499148-28-6P 499148-29-7P 499148-30-0P 499148-31-1P 499148-32-2P
499148-33-3P 499148-34-4P 499148-35-5P 499148-36-6P 499148-37-7P

499148-38-8P 499148-39-9P 499148-40-2P 499148-41-3P 499148-42-4P
499148-43-5P 499148-44-6P 499148-45-7P 499148-46-8P 499148-47-9P
499148-48-0P 499148-49-1P 499148-50-4P 499148-51-5P 499148-52-6P
499148-53-7P 499148-54-8P 499148-55-9P 499148-56-0P 499148-57-1P
499148-58-2P 499148-59-3P 499148-60-6P 499148-61-7P 499148-62-8P
499148-63-9P 499148-64-0P 499148-65-1P 499148-66-2P 499148-67-3P
499148-68-4P 499148-69-5P 499148-70-8P 499148-71-9P 499148-72-0P
499148-73-1P 499148-74-2P 499148-75-3P 499148-76-4P 499148-77-5P
499148-78-6P 499148-79-7P 499148-80-0P 499148-81-1P 499148-82-2P
499148-83-3P 499148-84-4P 499148-85-5P 499148-86-6P 499148-87-7P
499148-88-8P 499148-89-9P 499148-90-2P 499148-91-3P 499148-92-4P
499148-93-5P 499148-94-6P 499148-95-7P 499148-96-8P 499148-97-9P
499148-98-0P 499148-99-1P 499149-00-7P 499149-01-8P 499149-02-9P
499149-03-0P 499149-04-1P 499149-05-2P 499149-06-3P 499149-07-4P
499149-08-5P 499149-09-6P 499149-10-9P 499149-11-0P 499149-12-1P
499149-13-2P 499149-14-3P 499149-15-4P 499149-16-5P 499149-17-6P
499149-18-7P 499149-19-8P 499149-20-1P 499149-21-2P 499149-22-3P
499149-23-4P 499149-24-5P 499149-25-6P 499149-26-7P 499149-27-8P
499149-28-9P 499149-29-0P 499149-30-3P 499149-31-4P 499149-32-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499149-33-6P 499149-34-7P 499149-35-8P 499149-36-9P 499149-37-0P
499149-38-1P 499149-39-2P 499149-40-5P 499149-41-6P 499149-42-7P
499149-43-8P 499149-44-9P 499149-45-0P 499149-46-1P 499149-47-2P
499149-48-3P 499149-49-4P 499149-50-7P 499149-51-8P 499149-52-9P
499149-53-0P 499149-54-1P 499149-55-2P 499149-56-3P 499149-57-4P
499149-58-5P 499149-59-6P 499149-60-9P 499149-61-0P 499149-62-1P
499149-63-2P 499149-64-3P 499149-65-4P 499149-66-5P 499149-67-6P
499149-68-7P 499149-69-8P 499149-70-1P 499149-71-2P 499149-72-3P
499149-73-4P 499149-74-5P 499149-75-6P 499149-76-7P 499149-77-8P
499149-78-9P 499149-79-0P 499149-80-3P 499149-81-4P 499149-82-5P
499149-83-6P 499149-84-7P 499149-85-8P 499149-86-9P 499149-87-0P
499149-88-1P 499149-89-2P 499149-90-5P 499149-91-6P 499149-92-7P
499149-93-8P 499149-94-9P 499149-95-0P 499149-96-1P 499149-97-2P
499149-98-3P 499149-99-4P 499150-00-4P 499150-01-5P 499150-02-6P
499150-03-7P 499150-04-8P 499150-05-9P 499150-06-0P 499150-07-1P
499150-08-2P 499150-09-3P 499150-10-6P 499150-11-7P 499150-12-8P
499150-13-9P 499150-14-0P 499150-15-1P 499150-16-2P 499150-17-3P
499150-18-4P 499150-19-5P 499150-20-8P 499150-21-9P 499150-22-0P
499150-23-1P 499150-24-2P 499150-25-3P 499150-26-4P 499150-27-5P
499150-28-6P 499150-29-7P 499150-30-0P 499150-31-1P 499150-32-2P
499150-33-3P 499150-34-4P 499150-35-5P 499150-36-6P 499150-37-7P
499150-38-8P 499150-39-9P 499150-40-2P 499150-41-3P 499150-42-4P
499150-43-5P 499150-44-6P 499150-45-7P 499150-46-8P 499150-47-9P
499150-48-0P 499150-49-1P 499150-50-4P 499150-51-5P 499150-52-6P
499150-53-7P 499150-54-8P 499150-55-9P 499150-56-0P 499150-57-1P
499150-58-2P 499150-59-3P 499150-60-6P 499150-61-7P 499150-62-8P
499150-63-9P 499150-64-0P 499150-65-1P 499150-66-2P 499150-67-3P
499150-68-4P 499150-69-5P 499150-70-8P 499150-71-9P 499150-72-0P
499150-73-1P 499150-74-2P 499150-75-3P 499150-76-4P 499150-77-5P
499150-78-6P 499150-79-7P 499150-80-0P 499150-81-1P 499150-82-2P
499150-83-3P 499150-84-4P 499150-85-5P 499150-86-6P 499150-87-7P
499150-88-8P 499150-89-9P 499150-90-2P 499150-91-3P 499150-92-4P
499150-93-5P 499150-94-6P 499150-95-7P 499150-96-8P 499150-97-9P
499150-98-0P 499150-99-1P 499151-00-7P 499151-01-8P 499151-02-9P
499151-03-0P 499151-04-1P 499151-05-2P 499151-06-3P 499151-07-4P
499151-08-5P 499151-09-6P 499151-10-9P 499151-11-0P 499151-12-1P
499151-13-2P 499151-14-3P 499151-15-4P 499151-16-5P 499151-17-6P
499151-18-7P 499151-19-8P 499151-20-1P 499151-21-2P 499151-22-3P
499151-23-4P 499151-24-5P 499151-25-6P 499151-26-7P 499151-27-8P

499151-28-9P 499151-29-0P 499151-30-3P 499151-31-4P 499151-32-5P
499151-33-6P 499151-34-7P 499151-35-8P 499151-36-9P 499151-37-0P
499151-38-1P 499151-39-2P 499151-40-5P 499151-41-6P 499151-42-7P
499151-43-8P 499151-44-9P 499151-45-0P 499151-46-1P 499151-47-2P
499151-48-3P 499151-49-4P 499151-50-7P 499151-51-8P 499151-52-9P
499151-53-0P 499151-54-1P 499151-55-2P 499151-56-3P 499151-57-4P
499151-58-5P 499151-59-6P 499151-60-9P 499151-61-0P 499151-62-1P
499151-63-2P 499151-64-3P 499151-65-4P 499151-66-5P 499151-67-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499151-68-7P 499151-69-8P 499151-70-1P 499151-71-2P 499151-72-3P
499151-73-4P 499151-74-5P 499151-75-6P 499151-76-7P 499151-77-8P
499151-78-9P 499151-79-0P 499151-80-3P 499151-81-4P 499151-82-5P
499151-83-6P 499151-84-7P 499151-85-8P 499151-86-9P 499151-87-0P
499151-88-1P 499151-89-2P 499151-90-5P 499151-91-6P 499151-92-7P
499151-93-8P 499151-94-9P 499151-95-0P 499151-96-1P 499151-97-2P
499151-98-3P 499151-99-4P 499152-00-0P 499152-01-1P 499152-02-2P
499152-03-3P 499152-04-4P 499152-05-5P 499152-06-6P 499152-07-7P
499152-08-8P 499152-09-9P 499152-10-2P 499152-11-3P 499152-12-4P
499152-13-5P 499152-14-6P 499152-15-7P 499152-16-8P 499152-17-9P
499152-18-0P 499152-19-1P 499152-20-4P 499152-21-5P 499152-22-6P
499152-23-7P 499152-24-8P 499152-25-9P 499152-26-0P 499152-27-1P
499152-28-2P 499152-29-3P 499152-30-6P 499152-31-7P 499152-32-8P
499152-33-9P 499152-34-0P 499152-35-1P 499152-36-2P 499152-37-3P
499152-38-4P 499152-39-5P 499152-40-8P 499152-41-9P 499152-42-0P
499152-43-1P 499152-44-2P 499152-45-3P 499152-46-4P 499152-47-5P
499152-48-6P 499152-49-7P 499152-50-0P 499152-51-1P 499152-52-2P
499152-53-3P 499152-54-4P 499152-55-5P 499152-56-6P 499152-57-7P
499152-58-8P 499152-59-9P 499152-60-2P 499152-61-3P 499152-62-4P
499152-63-5P 499152-64-6P 499152-65-7P 499152-66-8P 499152-67-9P
499152-68-0P 499152-69-1P 499152-70-4P 499152-71-5P 499152-72-6P
499152-73-7P 499152-74-8P 499152-75-9P 499152-76-0P 499152-77-1P
499152-78-2P 499152-79-3P 499152-80-6P 499152-81-7P 499152-82-8P
499152-83-9P 499152-84-0P 499152-85-1P 499152-86-2P 499152-87-3P
499152-88-4P 499152-89-5P 499152-90-8P 499152-91-9P 499152-92-0P
499152-93-1P 499152-94-2P 499152-95-3P 499152-96-4P 499152-97-5P
499152-98-6P 499152-99-7P 499153-00-3P 499153-01-4P 499153-02-5P
499153-03-6P 499153-04-7P 499153-05-8P 499153-06-9P 499153-07-0P
499153-08-1P 499153-09-2P 499153-10-5P 499153-11-6P 499153-12-7P
499153-13-8P 499153-14-9P 499153-15-0P 499153-16-1P 499153-17-2P
499153-18-3P 499153-19-4P 499153-20-7P 499153-21-8P 499153-22-9P
499153-23-0P 499153-24-1P 499153-25-2P 499153-26-3P 499153-27-4P
499153-28-5P 499153-29-6P 499153-30-9P 499153-31-0P 499153-32-1P
499153-33-2P 499153-34-3P 499153-35-4P 499153-36-5P 499153-37-6P
499153-38-7P 499153-39-8P 499153-40-1P 499153-41-2P 499153-42-3P
499153-43-4P 499153-44-5P 499153-45-6P 499153-46-7P 499153-47-8P
499153-48-9P 499153-49-0P 499153-50-3P 499153-51-4P 499153-52-5P
499153-53-6P 499153-54-7P 499153-55-8P 499153-56-9P 499153-57-0P
499153-58-1P 499153-59-2P 499153-60-5P 499153-61-6P 499153-62-7P
499153-63-8P 499153-64-9P 499153-65-0P 499153-66-1P 499153-67-2P
499153-68-3P 499153-69-4P 499153-70-7P 499153-71-8P 499153-72-9P
499153-73-0P 499153-74-1P 499153-75-2P 499153-76-3P 499153-77-4P
499153-78-5P 499153-79-6P 499153-80-9P 499153-81-0P 499153-82-1P
499153-83-2P 499153-84-3P 499153-85-4P 499153-86-5P 499153-87-6P
499153-88-7P 499153-89-8P 499153-90-1P 499153-91-2P 499153-92-3P
499153-93-4P 499153-94-5P 499153-95-6P 499153-96-7P 499153-97-8P
499153-98-9P 499153-99-0P 499154-00-6P 499154-01-7P 499154-02-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499154-03-9P 499154-04-0P 499154-05-1P 499154-06-2P 499154-07-3P
499154-08-4P 499154-09-5P 499154-10-8P 499154-11-9P 499154-12-0P
499154-13-1P 499154-14-2P 499154-15-3P 499154-16-4P 499154-17-5P
499154-18-6P 499154-20-0P 499154-21-1P 499154-22-2P 499154-23-3P
499154-24-4P 499154-25-5P 499154-27-7P 499154-28-8P 499154-30-2P
499154-31-3P 499154-32-4P 499154-33-5P 499154-35-7P 499154-36-8P
499154-38-0P 499154-40-4P 499154-43-7P 499154-44-8P 499154-46-0P
499154-48-2P 499154-49-3P 499154-51-7P 499154-53-9P 499154-55-1P
499154-57-3P 499154-59-5P 499154-60-8P 499154-62-0P 499154-64-2P
499154-65-3P 499154-67-5P 499154-69-7P 499154-71-1P 499154-72-2P
499154-74-4P 499154-76-6P 499154-78-8P 499154-80-2P 499154-82-4P
499154-84-6P 499154-86-8P 499154-88-0P 499154-90-4P 499154-92-6P
499154-94-8P 499154-95-9P 499154-97-1P 499154-98-2P 499154-99-3P
499155-00-9P 499155-01-0P 499155-02-1P 499155-03-2P 499155-04-3P
499155-05-4P 499155-06-5P 499155-07-6P 499155-09-8P 499155-11-2P
499155-12-3P 499155-13-4P 499155-14-5P 499155-15-6P 499155-16-7P
499155-17-8P 499155-18-9P 499155-19-0P 499155-20-3P 499155-21-4P
499155-22-5P 499155-23-6P 499155-24-7P 499155-25-8P 499155-26-9P
499155-27-0P 499155-28-1P 499155-29-2P 499155-30-5P 499155-31-6P
499155-32-7P 499155-33-8P 499155-34-9P 499155-35-0P 499155-36-1P
499155-37-2P 499155-38-3P 499155-39-4P 499155-40-7P 499155-41-8P
499155-42-9P 499155-43-0P 499155-44-1P 499155-45-2P 499155-46-3P
499155-47-4P 499155-48-5P 499155-49-6P 499155-50-9P 499155-51-0P
499155-52-1P 499155-53-2P 499155-54-3P 499155-57-6P 499155-60-1P
499155-63-4P 499155-65-6P 499155-66-7P 499155-68-9P 499155-70-3P
499155-72-5P 499155-74-7P 499155-75-8P 499155-77-0P 499155-79-2P
499155-81-6P 499155-83-8P 499155-86-1P 499155-88-3P 499155-89-4P
499155-90-7P 499155-92-9P 499155-94-1P 499155-95-2P 499155-97-4P
499155-98-5P 499155-99-6P 499156-00-2P 499156-01-3P 499156-02-4P
499156-03-5P 499156-04-6P 499156-05-7P 499156-06-8P 499156-07-9P
499156-08-0P 499156-09-1P 499156-10-4P 499156-11-5P 499156-12-6P
499156-13-7P 499156-14-8P 499156-15-9P 499156-16-0P 499156-17-1P
499156-18-2P 499156-19-3P 499156-20-6P 499156-21-7P 499156-22-8P
499156-23-9P 499156-24-0P 499156-25-1P 499156-26-2P 499156-27-3P
499156-28-4P 499156-29-5P 499156-30-8P 499156-31-9P 499156-32-0P
499156-33-1P 499156-34-2P 499156-35-3P 499156-36-4P 499156-37-5P
499156-38-6P 499156-39-7P 499156-40-0P 499156-41-1P 499156-42-2P
499156-43-3P 499156-44-4P 499156-45-5P 499156-46-6P 499156-47-7P
499156-48-8P 499156-49-9P 499156-50-2P 499156-51-3P 499156-52-4P
499156-53-5P 499156-54-6P 499156-55-7P 499156-56-8P 499156-57-9P
499156-58-0P 499156-59-1P 499156-60-4P 499156-61-5P 499156-62-6P
499156-63-7P 499156-64-8P 499156-65-9P 499156-66-0P 499156-67-1P
499156-68-2P 499156-69-3P 499156-70-6P 499156-71-7P 499156-72-8P
499156-73-9P 499156-74-0P 499156-75-1P 499156-76-2P 499156-77-3P
499156-78-4P 499156-79-5P 499156-80-8P 499156-81-9P 499156-82-0P
499156-83-1P 499156-84-2P 499156-85-3P 499156-86-4P 499156-87-5P
499156-88-6P 499156-89-7P 499156-90-0P 499156-91-1P 499156-92-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 499156-93-3P 499156-94-4P 499156-95-5P 499156-96-6P 499156-97-7P
499156-98-8P 499156-99-9P 499157-00-5P 499157-01-6P 499157-02-7P
499157-03-8P 499157-04-9P 499157-05-0P 499157-06-1P 499157-09-4P
499157-10-7P 499157-11-8P 499157-12-9P 499157-13-0P 499157-14-1P
499157-15-2P 499157-16-3P 499157-17-4P 499157-18-5P 499157-19-6P
499157-20-9P 499157-21-0P 499157-22-1P 499158-01-9P 499158-02-0P
499158-03-1P 499158-04-2P 499159-54-5P 499159-55-6P 499159-56-7P
499159-59-0P 499159-60-3P 499159-61-4P 499159-62-5P 499159-63-6P

499159-64-7P 499159-65-8P 499159-88-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 64-17-5, Ethanol, reactions 74-88-4, Methyl iodide, reactions 75-36-5, Acetyl chloride 75-64-9, tert-Butylamine, reactions 75-65-0, tert-Butyl alcohol, reactions 93-35-6, 7-Hydroxycoumarin 95-48-7, 2-Methylphenol, reactions 98-10-2, Benzenesulfonamide 98-88-4, Benzoyl chloride 107-14-2, Chloroacetonitrile 107-30-2, Methoxymethyl chloride 108-95-2, Phenol, reactions 110-85-0, Piperazine, reactions 118-31-0, 1-Naphthylmethylamine 124-63-0, Mesyl chloride 127-08-2, Potassium acetate 140-88-5, Ethyl acrylate 141-82-2, Malonic acid, reactions 288-13-1, Pyrazole 358-23-6, Trifluoromethanesulfonic anhydride 556-96-7, 5-Bromo-m-xylene 563-47-3, 3-Chloro-2-methyl-1-propene 590-86-3, 3-Methylbutanal 630-08-0, Carbon monoxide, reactions 827-54-3, 2-Vinylnaphthalene 867-13-0 939-26-4, 2-Bromomethylnaphthalene 1074-82-4, Potassium phthalimide 1118-03-2, Trimethyltin azide 1485-07-0, 2-(2-Naphthyl)ethanol 1588-83-6, 4-Carboxy-2-nitroaniline 1694-92-4, 2-Nitrophenylsulfonyl chloride 1823-14-9, 5-Phenyl-1-pentyne 2243-83-6, 2-Naphthalenecarbonyl chloride 2374-03-0, 3-Hydroxy-4-aminobenzoic acid 2445-83-2, 7-Methylcoumarin 2687-43-6, Benzyloxyamine hydrochloride 2713-31-7, 2,5-Difluorophenol 5078-73-9 5470-11-1, Hydroxylamine hydrochloride 5779-95-3, 3,5-Dimethylbenzaldehyde 6160-65-2, N,N'-Thiocarbonyl diimidazole 14273-85-9, 4-Iodobutanoic acid methyl ester 14606-42-9 18162-48-6, tert-Butyldimethylsilyl chloride 29943-42-8, Tetrahydropyran-4-one 56613-80-0, (R)-Phenylglycinol 57848-46-1, 4-Bromo-2-fluorobenzaldehyde 60728-41-8 80235-10-5 499157-27-6 499157-45-8 499157-47-0 499157-56-1 499157-82-3 499157-94-7 499158-00-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

IT 2512-23-4P 5674-01-1P, 2-Methyl-2-propenylmagnesium chloride 53878-12-9P 72399-25-8P 80754-21-8P 91720-78-4P, 2-Naphthaleneethanethiol 157942-12-6P 191104-99-1P 499157-07-2P 499157-23-2P 499157-24-3P 499157-25-4P 499157-26-5P 499157-28-7P 499157-29-8P 499157-30-1P 499157-31-2P 499157-32-3P 499157-33-4P 499157-34-5P 499157-35-6P 499157-36-7P 499157-37-8P 499157-38-9P 499157-39-0P 499157-40-3P 499157-41-4P 499157-42-5P 499157-43-6P 499157-44-7P 499157-46-9P 499157-48-1P 499157-49-2P 499157-50-5P 499157-51-6P 499157-52-7P 499157-53-8P 499157-54-9P 499157-55-0P 499157-57-2P 499157-58-3P 499157-59-4P 499157-60-7P 499157-61-8P 499157-62-9P 499157-63-0P 499157-64-1P 499157-65-2P 499157-66-3P 499157-67-4P 499157-68-5P 499157-69-6P 499157-70-9P 499157-72-1P 499157-74-3P 499157-76-5P 499157-78-7P 499157-80-1P 499157-84-5P 499157-86-7P 499157-88-9P 499157-90-3P 499157-91-4P 499157-93-6P 499157-96-9P 499157-98-1P 499157-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)

```
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l9 and osteo?
         46611 OSTEO?
L11       8544 L9 AND OSTEO?

=> s l9 and osteopor?
         11766 OSTEOPOR?
L12       2738 L9 AND OSTEOPOR?

=> d scan
```

L12 2738 ANSWERS CAPLUS COPYRIGHT 2003 ACS
IC ICM G01N033-74
ICS G01N033-566; A61K038-00; C12Q001-68; C07K016-00; C07K014-00
CC 1-1 (Pharmacology)
TI Identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof
ST TIG2 gene protein polypeptide chemoattractant receptor ChemR23 disease diagnosis
IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(2; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(ChemR23; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Chemr23 mutation; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(TIG2 (tazarotene-induced gene 2); identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Fusion proteins (chimeric proteins)
Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TIG2; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Gene, animal
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(TIG2; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Protein sequences
(alignment; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Artery
(aorta, expression in; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Infection
(bacterial; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Aequorins
RL: DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(based assay; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)
IT Transplant and Transplantation
(bone; identification and interaction of TIG2 (Tazarotene-Induced

Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Intestine
(colon, expression in; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Adipose tissue
Adrenal gland
Bone marrow
Brain
Dendritic cell
Heart
Kidney
Liver
Lung
Lymph node
Monocyte
Muscle
Ovary
Pancreas
Pituitary gland
Placenta
Skin
Spleen
Stomach
T cell (lymphocyte)
Testis
Thymus gland
Thyroid gland
Trachea (anatomical)
(expression in; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Reporter gene
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(expression; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Fertility
(female, disorder; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Disease, animal
(genetic; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Proteins
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(green fluorescent; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Bone
(healing; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT AIDS (disease)
Anti-inflammatory agents
Antibacterial agents
Antitumor agents
Antiviral agents
Autoimmune disease
Diagnosis

Drug screening
Eczema
Energy transfer
Epitopes
Fluorescence
Fluorescence quenching
Fluorescent substances
Human
Inflammation
Microarray technology
Molecular cloning
Neoplasm
Osteoporosis
Ovary, neoplasm
Parasiticides
Polarized fluorescence
Protein sequences
Psoriasis
Signal transduction, biological
Skin, disease
Surface plasmon resonance
Test kits
Transplant rejection
Uterus, neoplasm
cDNA sequences
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Thioredoxins
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Radionuclides, biological studies
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Diglycerides
Phosphatidylinositols
mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Antibodies
Nucleic acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Neoplasm
(metastasis; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Intestine
(small, expression in; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Liposomes

(synthetic; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Bone
(transplant; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT Infection
(viral; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491666-76-3 491666-78-5 491666-79-6 491666-80-9 491666-81-0
491666-82-1 491666-83-2 491666-84-3 491666-85-4 491666-86-5
491666-87-6 491666-88-7 491666-89-8
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491666-74-1
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 69-79-4, Maltose
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(binding protein; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT **9001-78-9**, Alkaline phosphatase 50812-37-8, Glutathione S-transferase
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 60-92-4, CAMP 506-30-9, Arachidic acid **7440-70-2**, Calcium, biological studies 9012-42-4, Adenylate cyclase 27121-73-9, Inositol triphosphate 80449-02-1, Tyrosine kinase 141436-78-4, Protein kinase C 142243-02-5, MAP kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 186637-50-3, GenBank U77594 207788-36-1, GenBank Y14838 254579-96-9, GenBank AW113641 268395-62-6, GenBank AW915104 283131-95-3, GenBank AC075748 297065-29-3, GenBank BF018000 297087-93-5, GenBank BF020273 312851-10-8, GenBank BF713092 336036-14-7, GenBank BG691132 337099-55-5, GenBank BG713614 337100-01-3, GenBank BG713660 337100-43-3, GenBank BG713704
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491666-77-4 491666-90-1
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical

study); BIOL (Biological study); USES (Uses)
(nucleotide sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491666-75-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 71-00-1, Histidine, biological studies
RL: ANT (Analyte); ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(tags; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491667-67-5 491667-68-6 491667-69-7 491667-70-0 491667-71-1
491667-72-2 491667-73-3 491667-74-4 491667-75-5 491667-76-6
491667-83-5 491667-84-6 491667-85-7 491667-86-8 491667-87-9
491667-88-0 491667-89-1 491667-90-4 491667-91-5 491667-92-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491667-82-4
RL: PRP (Properties)
(unclaimed protein sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

IT 491593-15-8 491593-16-9 491593-17-0 491593-18-1 491593-19-2
491593-20-5 491593-21-6 491667-77-7 491667-78-8 491667-79-9
491667-80-2 491667-81-3 491667-93-7 491667-94-8 491667-95-9
491667-96-0 491667-97-1
RL: PRP (Properties)
(unclaimed sequence; identification and interaction of TIG2 (Tazarotene-Induced Gene-2) polypeptides with natural ligand of G-protein coupled receptor Chemr23 and uses thereof)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l9 and osteopor?/ab
8788 OSTEOPOR?/AB
L13 2083 L9 AND OSTEOPOR?/AB

=> d scan

L13 2083 ANSWERS CAPLUS COPYRIGHT 2003 ACS
IC ICM C07D239-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of quinazoline derivatives as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions
ST quinazoline prepn calcium sensing parathyroid hormone receptor antagonist osteoporosis
IT Parathyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium-sensing, antagonists; prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)
IT Human
Osteoporosis
(prepn. of quinazoline derivs. as antagonists of calcium-sensing

parathyroid hormone receptors useful for osteoporosis and other bone conditions)

IT Bone formation
(stimulation; prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Prepn. of quinazolines for preventing or treating bone conditions assocd. with increased calcium depletion or resorption)

IT 478963-31-4P, 6-Nitro-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-35-8P, 6-Amino-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-51-8P, 1-Isopropyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478963-55-2P, 6,7-Dihydroxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-62-1P, 1-Isopropyl-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-67-6P, 1-Benzyl-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-71-2P, 6-Hydroxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-73-4P, 6-Allyloxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-87-0P, 5-Allyl-6-hydroxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478964-14-6P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid methyl ester 478964-16-8P, 4-(4-Isopropylphenyl)-6-methoxy-1-(3-nitrobenzyl)-1H-quinazolin-2-one 478964-18-0P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 478964-41-9P, 1-(3-Aminobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478965-18-3P, 1-(2-Hydroxybenzyl)-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-22-9P, 1-(3-Hydroxybenzyl)-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-24-1P, 1-(4-Hydroxybenzyl)-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-26-3P, 1-[2-(6-Chlorohexyloxy)benzyl]-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-52-5P 478966-21-1P, 2-Chloro-4-(4-isopropylphenyl)-6,7-dimethoxyquinazoline 478966-47-1P, 2-Chloro-4-(4-isopropylphenyl)-6-methoxyquinazoline 478966-60-8P, [2-[[2-(3,5-Dimethoxyphenyl)-2-methylpropyl]amino]-4,5-dimethoxyphenyl](4-isopropylphenyl)methanone 478966-63-1P, 4-(4-Isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-41-8P, 1-(2-Hydroxy-2-phenylethyl)-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)

IT 478963-36-9P 478963-37-0P, 6-(Allylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-38-1P, 6-(Dimethylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-39-2P, 6-(Diethylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-40-5P, 6-(Dipropylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-41-6P, 6-(Ethylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-42-7P, 6-(Propylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-43-8P, 1-Isopropyl-4-(4-tert-butylphenyl)-6-nitro-1H-quinazolin-2-one 478963-44-9P, 6-Amino-1-benzyl-4-(4-tert-butylphenyl)-1H-quinazolin-2-one 478963-45-0P, 6-(Dipropargylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-46-1P, 6-(Propargylamino)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-47-2P, 6-(Propargylamino)-1-benzyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-48-3P, 6-(Allylamino)-1-benzyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-54-1P, (4-tert-Butylphenyl)(2-(isopropylamino)-4,5-dimethoxyphenyl)methanone 478963-56-3P, 6,7-Bis-Allyloxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-57-4P, 1-Isopropyl-4-(4-isopropylphenyl)-5-methyl-1H-quinazolin-2-one

478963-58-5P, 1-Isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-59-6P, 1-Isopropyl-4-(3-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-60-9P, 1-Isopropyl-4-(4-isopropylphenyl)-5-methoxy-1H-quinazolin-2-one 478963-61-0P, 1-Isopropyl-4-(4-isopropylphenyl)-6-methyl-1H-quinazolin-2-one 478963-63-2P, 1-Isopropyl-4-(4-isopropyl-2-methylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-64-3P, 4-(4-Ethylphenyl)-1-isopropyl-6-methoxy-1H-quinazolin-2-one 478963-65-4P, 4-(4-tert-Butylphenyl)-1-isopropyl-6-methoxy-1H-quinazolin-2-one 478963-66-5P, 1-Cyclopentyl-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-69-8P, 1-(3-Chloropropyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-74-5P, 1-Isopropyl-4-(4-isopropylphenyl)-6-propoxy-1H-quinazolin-2-one 478963-75-6P, 6-Ethoxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-76-7P, 6-Isopropoxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-77-8P, 6-Butoxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-79-0P, 1-Isopropyl-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478963-81-4P, 1-Isopropyl-4-(4-isopropylphenyl)-6-(2-methylallyloxy)-1H-quinazolin-2-one 478963-83-6P, 6-(2-Chloroethoxy)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-85-8P, 6-(3-Chloropropoxy)-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-86-9P, 6-Cyclopropylmethoxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-88-1P, 5-Allyl-1-isopropyl-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478963-89-2P, 5-Allyl-1-isopropyl-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478963-90-5P, [[1-Benzyl-4-(4-isopropylphenyl)-2-oxo-1,2-dihydroquinazolin-6-yl]oxy]acetonitrile 478963-92-7P, 1-(3-Chlorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478964-02-2P, (2-(Isopropylamino)-5-methoxyphenyl)(4-isopropylphenyl)methanone 478964-04-4P, 1-(3-Fluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478964-06-6P 478964-08-8P, 4-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzonitrile 478964-10-2P, 4-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]-3-methoxybenzoic acid methyl ester 478964-12-4P, [4-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]phenoxy]acetonitrile 478964-20-4P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzamide 478964-22-6P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]-N,N-dimethylbenzamide 478964-24-8P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 2-(dimethylamino)ethyl ester 478964-26-0P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]-N-methylbenzamide 478964-28-2P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid isopropyl ester 478964-30-6P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 2-(2-(dimethylamino)ethoxy)ethyl ester 478964-33-9P, 3-[[4-(4-Isopropylphenyl)-2-oxo-6-[(prop-2-ynyl)oxy]-2H-quinazolin-1-yl]methyl]benzoic acid 2-(2-(dimethylamino)ethoxy)ethyl ester trifluoroacetate 478964-35-1P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 4-(dimethylamino)butyl ester 478964-37-3P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 3-(dimethylamino)propyl ester 478964-39-5P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid 3-(4-methylpiperazin-1-yl)propyl ester 478964-43-1P, 1-(3-(Formylamino)benzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478964-64-6P, 1-Benzyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478964-78-2P, 1-Isobutyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478964-80-6P, 1-Ethyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478964-82-8P, 1-(2-Fluorobenzyl)-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478964-84-0P, 1-(4-Fluorobenzyl)-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478964-86-2P, 4-(4-tert-Butylphenyl)-1-isopropyl-6,7-dimethoxy-1H-quinazolin-2-one 478964-90-8P, 1-Isopropyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazoline-2-thione 478964-92-0P, 1-Benzyl-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-06-9P, 6-Allyloxy-1-benzyl-4-(4-isopropylphenyl)-

1H-quinazolin-2-one 478965-08-1P, Acetic acid 4-[[6-allyloxy-4-(4-isopropylphenyl)-2-oxo-2H-quinazolin-1-yl]methyl]phenyl ester 478965-10-5P, Acetic acid 4-[[4-(4-isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl ester 478965-12-7P 478965-14-9P 478965-20-7P, 1-(2-Hydroxybenzyl)-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478965-28-5P, 1-[2-(6-(Dimethylamino)hexyloxy)benzyl]-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-30-9P, 1-[2-(6-(Imidazol-1-yl)hexyloxy)benzyl]-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-33-2P 478965-36-5P 478965-38-7P, 4-(4-Isopropylphenyl)-1-[3-[2-(2-methoxyethoxy)ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-40-1P, 4-(4-Isopropylphenyl)-1-[3-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-42-3P, 4-(4-Isopropylphenyl)-1-[4-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-44-5P, 4-(4-Isopropylphenyl)-1-[3-(2-methoxyethoxy)benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-46-7P, 4-(4-Isopropylphenyl)-1-[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-48-9P, 4-(4-Isopropylphenyl)-1-[2-[2-(2-methoxyethoxy)ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-50-3P, 1-[3-(2-Hydroxyethoxy)benzyl]-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-54-7P, 4-(4-Isopropylphenyl)-1-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]benzyl]-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478965-57-0P, Methanesulfonic acid 2-[[4-(4-isopropylphenyl)-2-oxo-6-[(prop-2-ynyl)oxy]-2H-quinazolin-1-yl]methyl]phenyl ester 478965-66-1P, N-[3-[[4-(4-Isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]-4-[4-(2-methoxyethyl)piperazin-1-yl]butyramide 478965-68-3P, 4-(4-Isopropylphenyl)-1-[3-(2-oxopyrrolidin-1-yl)benzyl]-6-(propargyloxy)-1H-quinazolin-2-one 478965-70-7P, 2-[(3-(Dimethylamino)propyl)methylamino]-N-[3-[[4-(4-isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]acetamide 478965-72-9P, 2-(4-Allylpiperazin-1-yl)-N-[3-[[4-(4-isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]acetamide 478965-73-0P, N-[3-[[4-(4-Isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]-2-(4-methylpiperazin-1-yl)acetamide 478965-74-1P 478965-76-3P, N-[3-[[4-(4-Isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]-2-[4-(2-methoxyethyl)piperazin-1-yl]-N-methylacetamide 478965-79-6P 478965-81-0P, N-[3-[[4-(4-Cyclopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]-2-(4-methylpiperazin-1-yl)acetamide 478965-83-2P 478965-85-4P 478965-87-6P, N-[3-[[4-(4-Isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]-4-(morpholin-4-yl)butyramide 478965-89-8P, N-[3-[[6-Allyloxy-4-(4-isopropylphenyl)-2-oxo-2H-quinazolin-1-yl]methyl]phenyl]-4-(4-methylpiperazin-1-yl)butyramide 478965-91-2P, 4-(4-Isopropylphenyl)-1-(4-nitrobenzyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-93-4P, 1-(4-Aminobenzyl)-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-95-6P, 1-(2-Nitrobenzyl)-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-97-8P, 1-(2-Aminobenzyl)-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-99-0P, 1-Benzyl-4-(3-chloro-4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478966-14-2P, 1-(3-Fluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazoline-2-thione 478966-18-6P, 4-(4-Isopropylphenyl)-6-methoxy-1-(4-methoxyphenyl)-1H-quinazolin-2-one 478966-23-3P, 2-Isopropoxy-4-(4-isopropylphenyl)-6,7-dimethoxyquinazoline 478966-25-5P, 4-(4-Isopropylphenyl)-6,7-dimethoxy-2-phenoxyquinazoline 478966-27-7P, 2-Fluoro-4-(4-isopropylphenyl)-6,7-dimethoxyquinazoline 478966-29-9P, 4-(4-Isopropylphenyl)-6,7-dimethoxyquinazoline-2-carbonitrile 478966-31-3P, 4-(4-Isopropylphenyl)-6,7-dimethoxy-2-(6-methylpyridin-3-yloxy)quinazoline 478966-33-5P 478966-35-7P, 2-Isobutoxy-4-(4-isopropylphenyl)-6,7-dimethoxyquinazoline 478966-37-9P, 4-(4-Isopropylphenyl)-2,6,7-trimethoxyquinazoline 478966-39-1P, 4-(4-Isopropylphenyl)-2-isopropylsulfanyl-6,7-dimethoxyquinazoline

478966-41-5P, 2-Azido-4-(4-isopropylphenyl)-6,7-dimethoxyquinazoline
478966-43-7P, 4-(4-tert-Butylphenyl)-2-chloro-6,7-dimethoxyquinazoline
478966-45-9P, 4-(4-tert-Butylphenyl)-2,6,7-trimethoxyquinazoline
478966-49-3P 478966-51-7P, 4-(4-Isopropylphenyl)-6-methoxyquinazoline-2-carbonitrile 478966-52-8P, 4-(4-Isopropylphenyl)-6,7-dimethoxy-2-trifluoromethylquinazoline 478966-54-0P, 4-(4-Isopropylphenyl)-6,7-dimethoxy-2-methylquinazoline 478966-56-2P, 1-Cyclohexylmethyl-4-(4-isopropylphenyl)-6,7-dimethoxy-1H-quinazolin-2-one 478966-65-3P, 1-(4-Chlorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one
478966-67-5P, 1-(4-Bromobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478966-69-7P, 1-(4-Fluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478966-71-1P, Acetic acid 4-[[4-(4-isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]phenyl ester 478966-73-3P, 4-(4-Isopropylphenyl)-6-methoxy-1-(4-methoxybenzyl)-1H-quinazolin-2-one 478966-75-5P, 1-(4-Hydroxybenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478966-76-6P, 4-(4-Isopropylphenyl)-6-methoxy-1-(4-trifluoromethylbenzyl)-1H-quinazolin-2-one 478966-78-8P, 4-(4-Isopropylphenyl)-6-methoxy-1-(4-nitrobenzyl)-1H-quinazolin-2-one 478966-80-2P, 4-(4-Isopropylphenyl)-6-methoxy-1-(4-methylsulfanylbenzyl)-1H-quinazolin-2-one 478966-82-4P, 1-(4-Aminobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one
478966-84-6P, 4-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzoic acid methyl ester 478966-86-8P, 4-(4-Isopropylphenyl)-1-(4-methanesulfonylbenzyl)-6-methoxy-1H-quinazolin-2-one 478966-88-0P, 1-[4-(2-Chloroethoxy)benzyl]-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478966-90-4P, N-(2-(Dimethylamino)ethyl)-4-[[4-(4-isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzamide 478966-92-6P, 4-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]-N-(2-(pyrrolidin-1-yl)ethyl)benzamide 478966-94-8P, N-(2-(Ethylamino)ethyl)-4-[[4-(4-isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzamide 478966-96-0P, 1-(2-Hydroxybenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478966-98-2P, 1-(2-Chlorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one
478966-99-3P, 4-(4-Isopropylphenyl)-6-methoxy-1-(2-methylbenzyl)-1H-quinazolin-2-one 478967-00-9P, 4-(4-Isopropylphenyl)-6-methoxy-1-(2-nitrobenzyl)-1H-quinazolin-2-one 478967-01-0P, 2-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzonitrile 478967-02-1P, 4-(4-Isopropylphenyl)-6-methoxy-1-(3-methoxybenzyl)-1H-quinazolin-2-one
478967-04-3P, 3-[[4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]methyl]benzonitrile 478967-06-5P, 1-(2,6-Difluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-08-7P, 1-(2,4-Difluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one
478967-10-1P, 1-(3,4-Difluorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-12-3P, 1-(3,4-Dichlorobenzyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-14-5P, 4-(4-Isopropylphenyl)-6-methoxy-1-(2,4,6-trifluorobenzyl)-1H-quinazolin-2-one 478967-16-7P 478967-18-9P 478967-20-3P 478967-22-5P, 1-((6-Chloropyridin-3-yl)methyl)-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-24-7P, 4-(4-Isopropylphenyl)-6-methoxy-1-((5-nitrofuran-2-yl)methyl)-1H-quinazolin-2-one 478967-26-9P, 4-(4-Isopropylphenyl)-6-methoxy-1-(2-oxo-2-phenylethyl)-1H-quinazolin-2-one 478967-28-1P, 1-Isobutyl-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-31-6P, 1-[2-(1H-Indol-2-yl)ethyl]-4-(4-isopropylphenyl)-6-methoxy-1H-quinazolin-2-one 478967-34-9P, 4-(4-Isopropylphenyl)-6-methoxy-1-phenethyl-1H-quinazolin-2-one
478967-37-2P, [4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]acetic acid ethyl ester 478967-39-4P, [4-(4-Isopropylphenyl)-6-methoxy-2-oxo-2H-quinazolin-1-yl]acetonitrile 478967-45-2P, Acetic acid 2-[4-(4-isopropylphenyl)-2-oxo-6-[(prop-2-ynyl)oxy]-2H-quinazolin-1-yl]-1-phenylethyl ester 478967-47-4P, 4-(4-Isopropylphenyl)-1-(2-oxo-2-phenylethyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one 478967-49-6P, 1-[2-(4-Fluorophenyl)-2-oxoethyl]-4-(4-isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)

IT 75-30-9, 2-Iodopropane 75-31-0, Isopropylamine, reactions 96-09-3, Epoxystyrene 100-39-0, Benzyl bromide 104-83-6, 4-Chlorobenzyl chloride 104-92-7, 4-Bromoanisole 104-94-9, 4-Methoxyaniline 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 109-70-6, 1-Bromo-3-chloropropane 112-35-6, Triethylene glycol monomethyl ether 122-03-2, Cumic aldehyde 586-61-8, 4-Isopropylbromobenzene 766-80-3, 3-Chlorobenzyl bromide 927-58-2, 4-Bromobutyryl chloride 1882-69-5, 5-Methoxy-2-nitrobenzoic acid 2043-61-0, Cyclohexanecarboxaldehyde 2398-37-0, 3-Bromoanisole 2912-62-1, .alpha.-Chlorophenylacetyl chloride 3958-57-4, 3-Nitrobenzyl bromide 4543-96-8, N,N,N'-Trimethyl-1,3-propanediamine 6294-17-3, 1-Bromo-6-chlorohexane 6361-21-3, 2-Chloro-5-nitrobenzaldehyde 6482-24-2, 1-Bromo-2-methoxyethane 6705-03-9, 2-Amino-5-methoxybenzoic acid 13484-40-7, N-(2-Methoxyethyl)piperazine 16152-51-5, 4-Isopropylbenzeneboronic acid 17739-45-6, 2-(2-Bromoethoxy)tetrahydropyran 18620-03-6, 4-Isopropylphenylmagnesium bromide 26961-27-3, 2-Amino-4,5-dimethoxybenzonitrile 27631-29-4, 2,4-Dichloro-6,7-dimethoxyquinazoline 31106-82-8 42454-06-8, 5-Hydroxy-2-nitrobenzaldehyde 54149-17-6, 1-Bromo-2-(2-methoxyethoxy)ethane 74654-05-0, 2-[2-(2-Methoxyethoxy)ethoxy]ethyl methanesulfonate 478964-51-1, (2-Amino-3-methoxyphenyl)(4-isopropylphenyl)methanone 478966-16-4, [2-(3-Fluorobenzylamino)-5-methoxyphenyl](4-isopropylphenyl)methanone 478967-43-0, 4-(4-Isopropylphenyl)-6-[(prop-2-ynyl)oxy]-1H-quinazolin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)

IT 101-70-2P, Bis(4-methoxyphenyl)amine 16495-67-3P, Isopropyl(4-methoxyphenyl)amine 32618-84-1P, 6-Methoxy-1H-quinazoline-2,4-dione 37749-76-1P, 1-Isopropyl-4-(4-isopropylphenyl)-6-methoxy-3,4-dihydro-1H-quinazolin-2-one 85575-58-2P, 1-Isopropyl-1-(4-methoxyphenyl)urea 105763-77-7P, 2,4-Dichloro-6-methoxyquinazoline 214971-09-2P 408510-49-6P, 1,1-Bis(4-methoxyphenyl)urea 478963-32-5P, (2-Chloro-5-nitrophenyl)(4-isopropylphenyl)methanol 478963-33-6P, 2-Chloro-5-nitro-4'-isopropylbenzophenone 478963-34-7P 478963-52-9P, 2-(Isopropylamino)-4,5-dimethoxybenzonitrile 478963-53-0P 478963-91-6P, 1-Benzyl-6-hydroxy-4-(4-isopropylphenyl)-1H-quinazolin-2-one 478963-93-8P, (4-Isopropylphenyl)(3-methoxyphenyl)methanol 478963-94-9P, (4-Isopropylphenyl)(3-methoxyphenyl)methanone 478963-95-0P, (4-Isopropylphenyl)(5-methoxy-2-nitrophenyl)methanone 478963-96-1P, (4-Isopropylphenyl)(3-methoxy-2-nitrophenyl)methanone 478963-97-2P, (2-Amino-5-methoxyphenyl)(4-isopropylphenyl)methanone hydrochloride 478963-98-3P, [2-(3-Chlorobenzylamino)-5-methoxyphenyl](4-isopropylphenyl)methanone hydrochloride 478964-00-0P, [2-(3-Chlorobenzylamino)-5-methoxyphenyl](4-isopropylphenyl)methanone 478964-45-3P, (2-Amino-3-methoxyphenyl)(4-isopropylphenyl)methanone hydrochloride 478964-47-5P, (2-Amino-3-hydroxyphenyl)(4-isopropylphenyl)methanone 478964-49-7P, (3,4-Dihydro-2H-benzo[1,4]oxazin-5-yl)(4-isopropylphenyl)methanone 478964-53-3P, (2-Amino-5-methoxyphenyl)(4-isopropylphenyl)methanone 478964-56-6P 478964-58-8P 478964-62-4P 478964-66-8P, (2-Amino-4,5-dimethoxyphenyl)(4-isopropylphenyl)methanone 478964-68-0P, (2-(Benzylamino)-4,5-dimethoxyphenyl)(4-isopropylphenyl)methanone 478964-70-4P, [2-(3-Fluorobenzylamino)-4,5-dimethoxyphenyl](4-isopropylphenyl)methanone 478964-72-6P 478964-74-8P, [2-(3-Chlorobenzylamino)-4,5-dimethoxyphenyl](4-isopropylphenyl)methanone 478964-76-0P, (2-(Isopropylamino)-4,5-dimethoxyphenyl)(4-isopropylphenyl)methanone 478964-88-4P, 2-Chloro-N-[2-(4-isopropylbenzoyl)-4,5-dimethoxyphenyl]-2-

phenylacetamide 478964-94-2P, (2-Amino-5-(propargyloxy)phenyl)(4-isopropylphenyl)methanone 478964-96-4P, 2-Nitro-5-(propargyloxy)benzaldehyde 478964-98-6P, (4-Isopropylphenyl)(2-nitro-5-(propargyloxy)phenyl)methanol 478965-00-3P, (4-Isopropylphenyl)(2-nitro-5-(propargyloxy)phenyl)methanone 478965-02-5P, (2-(Benzylamino)-5-(propargyloxy)phenyl)(4-isopropylphenyl)methanone 478965-04-7P 478965-16-1P, [2-(2-Hydroxybenzylamino)-4,5-dimethoxyphenyl](4-isopropylphenyl)methanone 478965-59-2P, (4-Isopropylphenyl)[2-(3-nitrobenzylamino)-5-(propargyloxy)phenyl]methanone 478965-60-5P, 4-(4-Isopropylphenyl)-1-(3-nitrobenzyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-62-7P, 1-(3-Aminobenzyl)-4-(4-isopropylphenyl)-6-(propargyloxy)-1H-quinazolin-2-one 478965-64-9P, 4-Bromo-N-[3-[[4-(4-isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]butyramide 478965-71-8P, 2-Chloro-N-[3-[[4-(4-isopropylphenyl)-2-oxo-6-(propargyloxy)-2H-quinazolin-1-yl]methyl]phenyl]acetamide 478966-01-7P, (2-Amino-5-[(prop-2-ynyl)oxy]phenyl)(3-chloro-4-isopropylphenyl)methanone 478966-12-0P, (2-(Benzylamino)-5-[(prop-2-ynyl)oxy]phenyl)(3-chloro-4-isopropylphenyl)methanone hydrochloride 478966-58-4P, [2-[(Cyclohexylmethyl)amino]-4,5-dimethoxyphenyl](4-isopropylphenyl)methanone
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinazoline derivs. as antagonists of calcium-sensing parathyroid hormone receptors useful for osteoporosis and other bone conditions)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> s l9 and osteopor?/ti,ab and ?querc?/ti,ab
LEFT TRUNCATION IGNORED FOR '?QUERC?' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERC?' FOR FILE 'CAPLUS'
3156 OSTEOPOR?/TI
8788 OSTEOPOR?/AB
3263 QUERC?/TI
13795 QUERC?/AB
L14 3 L9 AND OSTEOPOR?/TI,AB AND ?QUERC?/TI,AB
Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> s l9 and osteopor?/ti,ab and (querc?/ti,ab or ?quercetin/ti,ab or ?quercitin/ti,ab or ?quercitrin/ti,ab or ?quercetrin/ti,ab)
LEFT TRUNCATION IGNORED FOR '?QUERCETIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCETIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCITIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCITIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCITRIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCITRIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCETRIN' FOR FILE 'CAPLUS'
LEFT TRUNCATION IGNORED FOR '?QUERCETRIN' FOR FILE 'CAPLUS'
3156 OSTEOPOR?/TI
8788 OSTEOPOR?/AB
3263 QUERC?/TI
13795 QUERC?/AB
1877 QUERCETIN/TI
9737 QUERCETIN/AB

```
            27 QUERCITIN/TI
           275 QUERCITIN/AB
            66 QUERCITRIN/TI
           899 QUERCITRIN/AB
             4 QUERCETRIN/TI
            82 QUERCETRIN/AB
L15          3 L9 AND OSTEOPOR?/TI,AB AND (QUERC?/TI,AB OR ?QUERCETIN/TI,AB OR
               ?QUERCITIN/TI,AB OR ?QUERCITRIN/TI,AB OR ?QUERCETRIN/TI,AB)
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l9 and osteopor?/ti,ab and (querc?/ti,ab or isoquerc?/ti,ab)
          3156 OSTEOPOR?/TI
          8788 OSTEOPOR?/AB
          3263 QUERC?/TI
         13795 QUERC?/AB
            60 ISOQUERC?/TI
           873 ISOQUERC?/AB
L16          4 L9 AND OSTEOPOR?/TI,AB AND (QUERC?/TI,AB OR ISOQUERC?/TI,AB)

=> d 1-4 bib ab hitstr

L16  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:384119  CAPLUS
DN   137:62599
TI   Flavonols and isoflavones prevent bone loss in the ovariectomized rat: A
     model for postmenopausal osteoporosis
AU   Horcajada-Molteni, Marie-Noelle; Coxam, Veronique
CS   Unite des Maladies Metaboliques et Micronutriments INRA Theix,
     Genes-Champanelle, Fr.
SO   Nutritional Aspects of Osteoporosis, [International Symposium on the
     Nutritional Aspects of Osteoporosis], 4th, Lausanne, Switzerland, May
     17-20, 2000 (2001), Meeting Date 2000, 325-340.  Editor(s): Burckhardt,
     Peter; Dawson-Hughes, Bess; Heaney, Robert P. Publisher: Academic Press,
     San Diego, Calif.
     CODEN: 69CPIW; ISBN: 0-12-141703-4
DT   Conference
LA   English
AB   Several studies suggest that polyphenols, present in fruits and
     vegetables, might exert a protective effect against hormone-dependent
     diseases.  The present expt. was carried out to assess the effects of
     rutin (quercetin-3-O-glucose rhamnose, a flavonol) and
     isoflavones (Soylife, Nederland BV) on bone metab. in ovariectomized rats,
     an animal model for postmenopausal osteoporosis.  Thirty rats
     were thus ovariectomized (OVX), while 10 controls were sham-operated (SH).
     Among the 30 OVX, 10 were fed for 90 days a synthetic diet (devoid of any
     vegetal proteins) contg. 0.25% rutin (OVXR); 10 received 0.5% isoflavones
     (OVXI), while the last 10 and the 10 SH rats were given identical control
     diets.  At necropsy, the decrease in uterine wt. was not different in OVX,
     OVXR, or OVXI, both treatments being devoid of any uterotrophic effect.
     Ovariectomy also induced a significant decrease in both total and distal
     metaphyseal femoral mineral d., which was prevented by rutine or
     isoflavone consumption.  Moreover, femoral failure load, which was not
     different in OVX and SH, was even higher in OVXR.  However, isoflavones
     did not elicit any improvement of this parameter.  On the other hand, on
     day 90, urinary deoxypyridinoline excretion (a marker for bone resorption)
```

was higher in OVX than in OVXR, OVXI, or SH. Simultaneously, plasma osteocalcin concn. (a marker for osteoblastic activity) was higher in OVX, OVXR, or OVXI than in SH. These results indicate that rutine (and/or its metabolites) and isoflavones, which appeared to be devoid of any uterotrophic activity, inhibit ovariectomy-induced trabecular bone loss in rats by slowing bone turnover, but mainly by decreasing resorption. Flavonols (rutine) even improved bone quality, as shown by bone strength assessment. In conclusion, the current dietary recommendations that emphasize an increase in the proportion and amt. of fruits and vegetables that should be consumed apply to skeletal diseases, as well. (c) 2001 Academic Press.

IT **153-18-4**, Rutin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dietary fruit and vegetables effect on bone metab. in relation to osteoporosis)

RN 153-18-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2002:171679 CAPLUS
DN 136:221722
TI Anti-**osteoporosis** compositions containing **quercetin** derivatives
IN Kim, Chung-sook; Ha, Hye-kyung; Song, Kye-yong
PA Korea Institute of Oriental Medicine, S. Korea
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002017909	A1	20020307	WO 2001-KR368	20010309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2001041236	A5	20020313	AU 2001-41236	20010309
	US 2002165169	A1	20021107	US 2002-70047	20020222
PRAI	KR 2000-46916	A	20000814		
	WO 2001-KR368	W	20010309		

OS MARPAT 136:221722

AB **Quercetin** deriv compns. can be used as therapeutic agents for **osteoporosis** treatment. The **quercetin** derivs. of the invention can be applied for the treatment and prevention of **osteoporosis**, since they effectively inhibit osteoclast proliferation and stimulate osteoblast proliferation more than the prior art therapeutic agents of **osteoporosis**, and increase trabecular bone area highly without changing hormone levels in the body and without any undesirable effects on the hematopoietic function and immune system. Thus, a syrup formulation contained **quercetin**-HCl 2, saccharin 0.8, sugar 25.4, glycerin 8.0, aroma compds. 0.04, EtOH 4.0, and sorbic acid 0.4 g, and water small quantities. The effectiveness of **quercetin** as a therapeutic agents for **osteoporosis** treatment was demonstrated.

IT **9001-78-9**, Alkaline phosphatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-osteoporosis compns. contg. quercetin derivs.)

RN 9001-78-9 CAPLUS

CN Phosphatase, alkaline (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **117-39-5**, Quercetin **402733-76-0**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-osteoporosis compns. contg. quercetin derivs.)

RN 117-39-5 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)



RN 402733-76-0 CAPLUS

CN Hydrochloric acid, compd. with 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one (9CI) (CA INDEX NAME)



●x HCl

IT **50-70-4**, Sorbitol, biological studies **50-81-7**, Vitamin C, biological studies **57-48-7**, Fructose, biological studies **57-50-1**, Sucrose, biological studies **63-42-3**, Lactose **67-97-0**, Vitamin D3 **69-65-8**, Mannitol **77-92-9**, Citric acid, biological studies **90-19-7**, Rhamnetin **94-13-3**, PropylParaben **99-76-3**, MethylParaben **117-39-5D**, Quercetin, derivs. **121-32-4**, Ethylvanillin **153-18-4**, Rutin **480-19-3**, Isorhamnetin **482-36-0** , Hyperoside **491-50-9**, Quercimeritrin **522-12-3**, Quercitrin **532-32-1**, Sodium benzoate **549-32-6**, Quercetin-3-O-.beta.-D-xylopyranoside **552-54-5**, Rhamnazin **557-04-0 572-30-5**, Avicularoside **572-32-7** **1245-15-4 1486-70-0**, Quercetin-3-methyl ether **2068-02-2 3306-29-4 4382-17-6** **6892-74-6**, Quercetin 3,7-diglucoside **7431-83-6**, Quercetin-3-O-gentiobioside **7440-70-2**, Calcium, biological studies **7585-39-9**, .beta.-Cyclodextrin **9003-39-8**, PVP **9004-32-4**, Carboxymethyl cellulose sodium salt **9004-34-6** , Cellulose, biological studies **9004-64-2**, Hydroxypropyl cellulose **9005-25-8**, Starch, biological studies **9050-04-8**, Carboxymethyl cellulose calcium salt **9063-38-1** , Sodium starch glycolate **10016-20-3**, .alpha.-Cyclodextrin **14807-96-6**, Talc, biological studies **20229-56-5**, Spireoside **21637-25-2**, Isoquercitrin **22255-13-6**, Guaijaverin **22688-79-5**, Quercetin-3-O-.beta.-D-glucuronide **22839-47-0**, Aspartame **27459-71-8 29125-80-2**, Quercetin 3,4'-di-O-.beta.-D-glucopyranoside **30311-61-6** **32453-36-4 32453-37-5 34199-21-8** **35589-21-0**, Isohyperoside **38934-20-2 42903-93-5** **53023-35-1 53209-27-1 56316-75-7** **59262-54-3**, Multinoside A **60889-05-6**, Quercetin-3-sulfate **61474-16-6 75110-60-0** **84534-23-6 90366-14-6 107190-71-6** **113447-39-5 117611-67-3 123493-51-6** **128308-95-2 134953-93-8 142997-33-9** **143016-73-3 145626-31-9 236752-10-6** **402733-67-9 402733-75-9 402824-92-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-osteoporosis compns. contg. quercetin derivs.)

RN 50-70-4 CAPLUS

CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-81-7 CAPLUS
CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-48-7 CAPLUS
CN D-Fructose (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-50-1 CAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63-42-3 CAPLUS
CN D-Glucose, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 67-97-0 CAPLUS
CN 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3.beta.,5Z,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 69-65-8 CAPLUS
CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77-92-9 CAPLUS
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 90-19-7 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-7-methoxy- (9CI) (CA INDEX NAME)



RN 94-13-3 CAPLUS
CN Benzoic acid, 4-hydroxy-, propyl ester (9CI) (CA INDEX NAME)



RN 99-76-3 CAPLUS
CN Benzoic acid, 4-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 117-39-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)



RN 121-32-4 CAPLUS
CN Benzaldehyde, 3-ethoxy-4-hydroxy- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 153-18-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA

INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 480-19-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 482-36-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-
galactopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491-50-9 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-3,5-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 522-12-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 532-32-1 CAPLUS
CN Benzoic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)



● Na

RN 549-32-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(.beta.-D-xylopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552-54-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 557-04-0 CAPLUS
CN Octadecanoic acid, magnesium salt (9CI) (CA INDEX NAME)

$HO_2C-(CH_2)_{16}-Me$

●1/2 Mg

RN 572-30-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(.alpha.-L-arabinofuranosyloxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 572-32-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 1486-70-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-methoxy- (9CI) (CA INDEX NAME)



RN 2068-02-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 3306-29-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)



RN 4382-17-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 6892-74-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,7-bis(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7431-83-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(6-O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 7585-39-9 CAPLUS
CN .beta.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 9003-39-8 CAPLUS
CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 88-12-0
CMF C6 H9 N O



RN 9004-32-4 CAPLUS
CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9004-34-6 CAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-64-2 CAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-25-8 CAPLUS
CN Starch (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9050-04-8 CAPLUS
CN Cellulose, carboxymethyl ether, calcium salt (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9063-38-1 CAPLUS

CN Starch, carboxymethyl ether, sodium salt (9CI) (CA INDEX NAME)

CM 1

CRN 9005-25-8
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 10016-20-3 CAPLUS
CN .alpha.-Cyclodextrin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 14807-96-6 CAPLUS
CN Talc (Mg3H2(SiO3)4) (9CI) (CA INDEX NAME)



●3/4 Mg

RN 20229-56-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-[4-(.beta.-D-glucopyranosyloxy)-3-hydroxyphenyl]-

3,5,7-trihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 21637-25-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucofuranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 22255-13-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(.alpha.-L-arabinopyranosyloxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 22688-79-5 CAPLUS
CN .beta.-D-Glucopyranosiduronic acid, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 22839-47-0 CAPLUS
CN L-Phenylalanine, L-.alpha.-aspartyl-, 2-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 27459-71-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

CM 1

CRN 492-61-5
CMF C6 H12 O6

Absolute stereochemistry. Rotation (+).



CM 2

CRN 482-35-9
CMF C21 H20 O12

Absolute stereochemistry. Rotation (-).



RN 29125-80-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-(.beta.-D-glucopyranosyloxy)-2-[4-(.beta.-D-glucopyranosyloxy)-3-hydroxyphenyl]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 30311-61-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 32453-36-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[2-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 32453-37-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(O-6-deoxy-.alpha.-L-mannopyranosyl-(1.fwdarw.2)-O-6-deoxy-.alpha.-L-mannopyranosyl-(1.fwdarw.6)-.beta.-D-glucopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 34199-21-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-(.beta.-D-glucopyranosyloxy)-3,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35589-21-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactofuranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38934-20-2 CAPLUS

CN .beta.-D-Glucopyranosiduronic acid, 2-(3,4-dihydroxyphenyl)-3,5-dihydroxy-4-oxo-4H-1-benzopyran-7-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42903-93-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(2-O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 53023-35-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(O-.beta.-D-glucopyranosyl-.beta.-D-galactopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

CM 1

CRN 492-61-5
CMF C6 H12 O6

Absolute stereochemistry. Rotation (+).



CM 2

CRN 482-36-0
CMF C21 H20 O12

Absolute stereochemistry.



RN 53209-27-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[[2-O-(3,4,5-trihydroxybenzoyl)-.beta.-D-galactopyranosyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56316-75-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[[6-O-(3,4,5-trihydroxybenzoyl)-.beta.-D-glucopyranosyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59262-54-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(6-deoxy-4-O-.beta.-D-glucopyranosyl-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 60889-05-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(sulfooxy)-
(9CI) (CA INDEX NAME)



RN 61474-16-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(O-.beta.-D-
glucopyranosyl-(1.fwdarw.6)-O-.beta.-D-glucopyranosyl-(1.fwdarw.6)-.beta.-
D-glucopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 75110-60-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-
galactopyranosyloxy)-7-[(O-.beta.-D-glucopyranosyl-.beta.-D-
glucopyranosyl)oxy]-5-hydroxy- (9CI) (CA INDEX NAME)

CM 1

CRN 56782-99-1
CMF C27 H30 O17

Absolute stereochemistry.



CM 2

CRN 492-61-5
CMF C6 H12 O6

Absolute stereochemistry. Rotation (+).



RN 84534-23-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(6-O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 90366-14-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(6-O-.beta.-D-glucopyranosyl-.beta.-D-galactopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107190-71-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-deoxy-2-O-[6-O-[3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A



RN 113447-39-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-deoxy-4-O-[6-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 117611-67-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[2-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-galactopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123493-51-6 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(O-6-deoxy-.alpha.-L-mannopyranosyl-(1.fwdarw.2)-O-[.beta.-D-glucopyranosyl-(1.fwdarw.6)]-.beta.-D-galactopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 128308-95-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(O-6-deoxy-.alpha.-L-mannopyranosyl-(1.fwdarw.4)-O-6-deoxy-.alpha.-L-mannopyranosyl-(1.fwdarw.6)-.beta.-D-galactopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)



RN 134953-93-8 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-[(O-.beta.-D-glucopyranosyl-(1.fwdarw.3)-O-6-deoxy-.alpha.-L-mannopyranosyl-

(1.fwdarw.6)-.beta.-D-galactopyranosyl)oxy]-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142997-33-9 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[[6-deoxy-2-O-[6-O-[(2E)-3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)



— Me

— OH

RN 143016-73-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-deoxy-2-O-[6-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)



RN 145626-31-9 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[4-O-(6-O-acetyl-.beta.-D-glucopyranosyl)-6-deoxy-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 236752-10-6 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-(.alpha.-L-arabinopyranosyloxy)-2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402733-67-9 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(O-D-glucopyranosyl-(1.fwdarw.6)-O-.beta.-D-glucopyranosyl-(1.fwdarw.4)-6-deoxy-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402733-75-9 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-deoxy-2-O-[6-O-[3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]-.alpha.-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 402824-92-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-[(O-.beta.-D-glucopyranosyl-.beta.-D-glucopyranosyl)oxy]-3-(.beta.-D-glucopyranosyloxy)-5-hydroxy- (9CI) (CA INDEX NAME)

CM 1

CRN 6892-74-6
CMF C27 H30 O17

Absolute stereochemistry.



CM 2

CRN 492-61-5
CMF C6 H12 O6

Absolute stereochemistry. Rotation (+).



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2001:885728 CAPLUS
DN 136:11204
TI Composition for the treatment and/or the prevention of **osteoporosis** and/or inflammatory joint diseases
IN Buchholz, Herwig; Meduski, Jerzy; Frohne, Marcus
PA Merck Patent Gmbh, Germany
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001091734	A2	20011206	WO 2001-EP5753	20010519
	WO 2001091734	A3	20021205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1286667	A2	20030305	EP 2001-953150	20010519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-208572P	P	20000602		
	WO 2001-EP5753	W	20010519		

AB Compns. and pharmaceutical compns. are described which comprise: a component A comprising one or more flavonol glycosides, a component B comprising one or more tetrahydrofolic acid compds., a component C comprising one or more calcium supplements, and a component D comprising one or more magnesium supplements. Methods of using such compns. and pharmaceutical compns. to treat and/or prevent **osteoporosis** and/or an inflammatory joint disease are also described. An oral formulation contained **isoquercetin** 500 mg, Ca 5-methyltetrahydrofolate 800 .mu.g, Ca citrate tetrahydrate 4000 mg, and Mg chloride hexahydrate 3000 mg.

IT **153-18-4**, Rutin **482-36-0**, Hyperin **491-50-9**, Quercimeritrin **522-12-3**, Quercitrin **7440-70-2**, Calcium, biological studies **20229-56-5**, Spiraeosid **21637-25-2**, Isoquercitrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compn. for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases)

RN 153-18-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 482-36-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-galactopyranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 491-50-9 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-7-(.beta.-D-glucopyranosyloxy)-3,5-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 522-12-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 20229-56-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-[4-(.beta.-D-glucopyranosyloxy)-3-hydroxyphenyl]-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 21637-25-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-D-glucofuranosyloxy)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2000:202990 CAPLUS
DN 132:320400
TI Estrogen synthesis in human colon cancer epithelial cells
AU Fiorelli, G.; Picariello, L.; Martineti, V.; Tonelli, F.; Brandi, M. L.
CS Endocrine Unit, Department of Clinical Physiopathology, Medical School, University of Florence, Florence, 50139, Italy
SO Journal of Steroid Biochemistry and Molecular Biology (2000), Volume Date 1999, 71(5-6), 223-230
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier Science Ltd.
DT Journal
LA English
AB Epidemiol. and exptl. data suggest an involvement of estrogen in the development and progression of colorectal cancer. In order to det. whether local synthesis of estrogen occurred in human colonic cancer cells, two colorectal cancer cell lines, HCT8 and HCT116, were evaluated for gene expression and enzyme activity of cytochrome P 450 aromatase. In addn., the effect on aromatase expression of charcoal-stripped fetal calf serum, of **quercetin** and genistein and of tamoxifen and raloxifene was investigated in both cell lines. RT-PCR anal. revealed that colorectal adenocarcinoma cell lines contain aromatase as a major component. The conversion of [3H]androstenedione to estrone and labeled water was dose-dependently inhibited by 4-hydroxyandrostenedione and obeyed Michaelis-Menten kinetic with apparent Km values of .apprx.20 nM and Vmax values of approx. 200 and 500 fmol/mg protein/h for HCT8 and HCT116 cells, resp. After 24 h incubation, genistein (1 .mu.M) significantly increased aromatase activity in HCT8 cells, with no effect on HCT116 cells. In accord with previous observation in reproductive tissues, **quercetin** (1 .mu.M) significantly inhibited the enzyme activity in both cell lines. Also tamoxifen (100 nM) acted as inhibitor, while raloxifene (10 nM) decreased the enzyme activity only in HCT116 cells. The aromatase gene expression modulation by these effective agents was consistent with their effects on enzyme activity. These findings demonstrate for the first time that colorectal adenocarcinoma cell lines express aromatase. Interestingly, the enzyme activity was inhibited by **quercetin**, one major dietary flavonoid, by tamoxifen, a hormonal therapeutic agent for breast cancer, and by raloxifene, used in the prevention of postmenopausal **osteoporosis**.
IT **117-39-5**, Quercetin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of estrogen synthesis in human colon cancer epithelial

cells)
RN 117-39-5 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy- (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	232.20	273.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:11:05 ON 17 APR 2003

Welcome to STN International! Enter x:x

LOGINID:ssspta1803kkf

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:55:05 ON 17 APR 2003
FILE 'CAPLUS' ENTERED AT 11:55:05 ON 17 APR 2003
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	232.20	273.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	232.20	273.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

FILE 'REGISTRY' ENTERED AT 11:55:18 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8
DICTIONARY FILE UPDATES: 16 APR 2003 HIGHEST RN 503266-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s 572-32-7/rn
L17 1 572-32-7/RN

=> d

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **572-32-7** REGISTRY
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-
dimethoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Flavone, 3',5-dihydroxy-3,4',7-trimethoxy- (7CI, 8CI)

OTHER NAMES:
CN 3,7,4'-Tri-O-methylquercetin
CN 3,7,4'-Trimethylquercetin
CN 5,3'-Dihydroxy-3,7,4'-trimethoxyflavone
CN Ayanin
CN Ayarin
CN Quercetin 3,7,4'-trimethyl ether
FS 3D CONCORD
DR 117047-32-2
MF C18 H16 O7
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, IPA, NAPRALERT, TOXCENTER, USPATFULL
      (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

75 REFERENCES IN FILE CA (1962 TO DATE)
76 REFERENCES IN FILE CAPLUS (1962 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s 1245-15-4/rn
L18 1 1245-15-4/RN

=> d

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN **1245-15-4** REGISTRY
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Flavone, 5-hydroxy-3,3',4',7-tetramethoxy- (7CI, 8CI)
OTHER NAMES:
CN 3,3',4',7-Tetramethylquercetin
CN 5-Hydroxy-3,3',4',7-tetramethoxyflavone
CN Quercetin 3,7,3',4'-tetramethyl ether
CN Retusin
CN Retusin (Ariocarpus)
CN Retusine
FS 3D CONCORD
MF C19 H18 O7
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, IPA, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
      (*File contains numerically searchable property data)
    Other Sources: EINECS**
      (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

154 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
155 REFERENCES IN FILE CAPLUS (1962 TO DATE)
13 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.56	277.60
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.60

FILE 'CAPLUS' ENTERED AT 11:56:59 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Apr 2003 VOL 138 ISS 16
FILE LAST UPDATED: 16 Apr 2003 (20030416/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:51:36 ON 17 APR 2003)

FILE 'REGISTRY' ENTERED AT 10:51:45 ON 17 APR 2003
E QUERCETIN/CN
L1 1 S E3
E QUERCITIN/CN
L2 1 S E3
E ISORHAMNETIN/CN
L3 1 S E3
E QUERCIMERITRIN/CN
L4 1 S E3
E RHAMNETIN/CN
L5 1 S E3

```
                E SPIREAOSIDE/CN
                E QUERCETIN-7-O-/CN
L6            1 S E4
                E QUERCETIN-3/CN

     FILE 'CAPLUS' ENTERED AT 10:58:24 ON 17 APR 2003
                E KIM C?/AU AND HA H?/AU AND SONG K?/AU
                E KIM C?/AU AND HA H?/AU AND SONG K?/AU
L7            1 S KIM C?/AU AND HA H?/AU AND SONG K?/AU
L8              TRA L7 1- RN :       80 TERMS
L9       707998 SEA L8
L10       21359 S L9 AND (BONE OR BONY OR OSTEO? OR OSSI? OR OSSEO?)
L11        8544 S L9 AND OSTEO?
L12        2738 S L9 AND OSTEOPOR?
L13        2083 S L9 AND OSTEOPOR?/AB
L14           3 S L9 AND OSTEOPOR?/TI,AB AND ?QUERC?/TI,AB
L15           3 S L9 AND OSTEOPOR?/TI,AB AND (QUERC?/TI,AB OR ?QUERCETIN/TI,AB
L16           4 S L9 AND OSTEOPOR?/TI,AB AND (QUERC?/TI,AB OR ISOQUERC?/TI,AB)

     FILE 'REGISTRY' ENTERED AT 11:55:18 ON 17 APR 2003
L17           1 S 572-32-7/RN
L18           1 S 1245-15-4/RN

     FILE 'CAPLUS' ENTERED AT 11:56:59 ON 17 APR 2003

=> s (l17 or l18) and osteopor?
           76 L17
          155 L18
        11766 OSTEOPOR?
L19         1 (L17 OR L18) AND OSTEOPOR?

=> d scan

L19   1 ANSWERS   CAPLUS  COPYRIGHT 2003 ACS
IC    ICM  A61K031-353
CC    63-6 (Pharmaceuticals)
      Section cross-reference(s): 1
TI    Anti-osteoporosis compositions containing quercetin derivatives
ST    osteoporosis inhibitor quercetin deriv
IT    Body weight
      Cell proliferation
      Flavor
      Lubricants
      Osteoclast
      Preservatives
      Stabilizing agents
      Sweetening agents
         (anti-osteoporosis compns. contg. quercetin derivs.)
IT    Soybean oil
      Waxes
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (anti-osteoporosis compns. contg. quercetin derivs.)
IT    Drug delivery systems
         (capsules, soft; anti-osteoporosis compns. contg. quercetin
         derivs.)
IT    Drug delivery systems
         (capsules; anti-osteoporosis compns. contg. quercetin
         derivs.)
IT    Drug delivery systems
         (emulsions; anti-osteoporosis compns. contg. quercetin
         derivs.)
IT    Drug delivery systems
         (injections; anti-osteoporosis compns. contg. quercetin
         derivs.)
```

IT Drug delivery systems
(liqs.; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(ointments; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(oral; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(parenterals; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(powders; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(suppositories; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(suspensions; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(syrups; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Drug delivery systems
(tablets; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT **Osteoporosis**
(therapeutic agents; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT Bone
(trabecula; anti-**osteoporosis** compns. contg. quercetin derivs.)
IT 9001-78-9, Alkaline phosphatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-**osteoporosis** compns. contg. quercetin derivs.)
IT 117-39-5, Quercetin 402733-76-0
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-**osteoporosis** compns. contg. quercetin derivs.)
IT 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 67-97-0, Vitamin D3 69-65-8, Mannitol 77-92-9, Citric acid, biological studies 90-19-7, Rhamnetin 94-13-3, PropylParaben 99-76-3, MethylParaben 117-39-5D, Quercetin, derivs. 121-32-4, Ethylvanillin 153-18-4, Rutin 480-19-3, Isorhamnetin 482-36-0, Hyperoside 491-50-9, Quercimeritrin 522-12-3, Quercitrin 532-32-1, Sodium benzoate 549-32-6, Quercetin-3-O-.beta.-D-xylopyranoside 552-54-5, Rhamnazin 557-04-0 572-30-5, Avicularoside **572-32-7 1245-15-4** 1486-70-0, Quercetin-3-methyl ether 2068-02-2 3306-29-4 4382-17-6 6892-74-6, Quercetin 3,7-diglucoside 7431-83-6, Quercetin-3-O-gentiobioside 7440-70-2, Calcium, biological studies 7585-39-9, .beta.-Cyclodextrin 9003-39-8, PVP 9004-32-4, Carboxymethyl cellulose sodium salt 9004-34-6, Cellulose, biological studies 9004-64-2, Hydroxypropyl cellulose 9005-25-8, Starch, biological studies 9050-04-8, Carboxymethyl cellulose calcium salt 9063-38-1, Sodium starch glycolate 10016-20-3, .alpha.-Cyclodextrin 14807-96-6, Talc, biological studies 20229-56-5, Spireoside 21637-25-2, Isoquercitrin 22255-13-6, Guaijaverin 22688-79-5, Quercetin-3-O-.beta.-D-glucuronide 22839-47-0, Aspartame 27459-71-8 29125-80-2, Quercetin 3,4'-di-O-.beta.-D-glucopyranoside 30311-61-6 32453-36-4 32453-37-5 34199-21-8 35589-21-0, Isohyperoside 38934-20-2 42903-93-5 53023-35-1 53209-27-1 56316-75-7 59262-54-3, Multinoside A 60889-05-6, Quercetin-3-sulfate 61474-16-6 75110-60-0 84534-23-6 90366-14-6 107190-71-6 113447-39-5 117611-67-3 123493-51-6 128308-95-2 134953-93-8 142997-33-9 143016-73-3 145626-31-9 236752-10-6 402733-67-9 402733-75-9 402824-92-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-**osteoporosis** compns. contg. quercetin derivs.)

ALL ANSWERS HAVE BEEN SCANNED

=> d ti

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
TI Anti-**osteoporosis** compositions containing quercetin derivatives

=> d bib

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2002:171679 CAPLUS
DN 136:221722
TI Anti-**osteoporosis** compositions containing quercetin derivatives
IN Kim, Chung-sook; Ha, Hye-kyung; Song, Kye-yong
PA Korea Institute of Oriental Medicine, S. Korea
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002017909	A1	20020307	WO 2001-KR368	20010309
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041236	A5	20020313	AU 2001-41236	20010309
	US 2002165169	A1	20021107	US 2002-70047	20020222
PRAI	KR 2000-46916	A	20000814		
	WO 2001-KR368	W	20010309		

OS MARPAT 136:221722
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (l17 or l18) and (therap? or pharmaceut?)
76 L17
155 L18
322152 THERAP?
221620 PHARMACEUT?
L20 12 (L17 OR L18) AND (THERAP? OR PHARMACEUT?)

=> d 1-12 bib ab hitstr

L20 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2002:669877 CAPLUS
DN 137:345604
TI Antiproliferative Activities of Citrus Flavonoids against Six Human Cancer Cell Lines
AU Manthey, John A.; Guthrie, Najla
CS U.S. Citrus and Subtropical Products Laboratory, South Atlantic Area Agricultural Research Service, U.S. Department of Agriculture, Winter Haven, FL, 33881, USA
SO Journal of Agricultural and Food Chemistry (2002), 50(21), 5837-5843

CODEN: JAFCAU; ISSN: 0021-8561
PB American Chemical Society
DT Journal
LA English
AB Citrus fruits contain high concns. of several classes of phenols, including numerous hydroxycinnamates, flavonoid glycosides, and polymethoxylated flavones. The latter group of compds. occurs without glycosidic linkages and has been shown to inhibit the proliferation of a no. of cancer cell lines. This antiproliferative property was further demonstrated against addnl. human cancer cell lines, and the antiproliferative actions of a series of synthetic methoxylated flavones were also studied. Similar to the naturally occurring compds., the synthetic compds. exhibited strong antiproliferative activities. In many cases the IC50 values occurred below 10 .mu.m. Other hydroxylated flavone and flavanone aglycons also exhibited antiproliferative activities against the cancer cell lines, with the flavones showing greater activities than the flavanones. Glycosylation of these compds. removed their activity. The strong antiproliferative activities of the polymethoxylated flavones suggest that they may have use as anticancer agents in humans.
IT **1245-15-4P**, Quercetin 3,7,3',4'-tetramethylether
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antiproliferative activities of Citrus flavonoids against six human cancer cell lines)
RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2002:497655 CAPLUS
DN 138:49391
TI Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity
AU Matsuda, Hisashi; Morikawa, Toshio; Toguchida, Iwao; Yoshikawa, Masayuki
CS Kyoto Pharmaceutical University, Kyoto, 607-8412, Japan
SO Chemical & Pharmaceutical Bulletin (2002), 50(6), 788-795
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 138:49391
AB The methanolic exts. of several natural medicines and medicinal foodstuffs were found to show an inhibitory effect on rat lens aldose reductase. In most cases, flavonoids were isolated as the active constituents by bioassay-guided sepn., and among them, quercitrin (IC50=0.15 .mu.M), guaijaverin (0.18 .mu.M), and desmanthin-1 (0.082 .mu.M) exhibited potent inhibitory activity. Desmanthin-1 showed the most potent activity, which was equiv. to that of a com. synthetic aldose reductase inhibitor, epalrestat (0.072 .mu.M). In order to clarify the structural requirements of flavonoids for aldose reductase inhibitory activity, various flavonoids

and related compds. were examd. The results suggested the following structural requirements of flavonoid:. 1. The flavones and flavonols having the 7-hydroxyl and/or catechol moiety at the B ring (the 3',4'-dihydroxyl moiety) exhibit the strong activity;. 2. The 5-hydroxyl moiety does not affect the activity;. 3. The 3-hydroxyl and 7-O-glucosyl moieties reduce the activity;. 4. The 2-3 double bond enhances the activity;. 5. The flavones and flavonols having the catechol moiety at the B ring exhibit stronger activity than those having the pyrogallol moiety (the 3',4',5'-trihydroxyl moiety).

IT **572-32-7P**, Ayanin **1245-15-4P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(flavonoids and related compds. structure-related aldose reductase inhibitory activity)

RN 572-32-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2002:332008 CAPLUS
DN 136:345763
TI Use of an association of at least a carotenoid and of at least an isoflavonoid for treating cutaneous symptoms of ageing
IN Breton, Lionel; Baur, Markus; Liviero, Christel
PA L'Oreal, Fr.
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002034233	A2	20020502	WO 2001-FR3319	20011025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	FR 2815861	A1	20020503	FR 2000-13755	20001026
	AU 2002014106	A5	20020506	AU 2002-14106	20011025
PRAI	FR 2000-13755	A	20001026		
	WO 2001-FR3319	W	20011025		

AB The invention concerns the use in a compn. or for prepg. a compn. of the assocn. of at least a carotenoid and at least an isoflavonoid, the assocn. or the compn. being designed to treat cutaneous symptoms of ageing, particularly degrdn. of the skin and/or of mucous membranes by inhibiting the activity and/or the expression of collagenases and by increasing collagen synthesis. These compns. may be prepd. in oral or topical formulations and contain active components such as lycopene and soybean exts.

IT **1245-15-4**
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carotenoid and isoflavonoid formulations for treating cutaneous symptoms of ageing)

RN 1245-15-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 2002:171679 CAPLUS

DN 136:221722

TI Anti-osteoporosis compositions containing quercetin derivatives

IN Kim, Chung-sook; Ha, Hye-kyung; Song, Kye-yong

PA Korea Institute of Oriental Medicine, S. Korea

SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002017909	A1	20020307	WO 2001-KR368	20010309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2001041236	A5	20020313	AU 2001-41236	20010309
	US 2002165169	A1	20021107	US 2002-70047	20020222
PRAI	KR 2000-46916	A	20000814		
	WO 2001-KR368	W	20010309		

OS MARPAT 136:221722

AB Quercetin deriv compns. can be used as **therapeutic** agents for

osteoporosis treatment. The quercetin derivs. of the invention can be applied for the treatment and prevention of osteoporosis, since they effectively inhibit osteoclast proliferation and stimulate osteoblast proliferation more than the prior art **therapeutic** agents of osteoporosis, and increase trabecular bone area highly without changing hormone levels in the body and without any undesirable effects on the hematopoietic function and immune system. Thus, a syrup formulation contained quercetin-HCl 2, saccharin 0.8, sugar 25.4, glycerin 8.0, aroma compds. 0.04, EtOH 4.0, and sorbic acid 0.4 g, and water small quantities. The effectiveness of quercetin as a **therapeutic** agents for osteoporosis treatment was demonstrated.

IT **572-32-7 1245-15-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-osteoporosis compns. contg. quercetin derivs.)

RN 572-32-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2001:401657 CAPLUS
DN 135:189736
TI Radical scavenging and xanthine oxidase inhibitory activity of phenolic compounds from Bridelia ferruginea stem bark
AU Cimanga, K.; Ying, L.; De Bruyne, T.; Apers, S.; Cos, P.; Hermans, N.; Bakana, P.; Tona, L.; Kambu, K.; Kalenda, D. T.; Pieters, L.; Vanden Berghe, D.; Vlietinck, A. J.
CS Department of Pharmaceutical Sciences, University of Antwerp (UIA), Antwerp, B-2610, Belg.
SO Journal of Pharmacy and Pharmacology (2001), 53(5), 757-761
CODEN: JPPMAB; ISSN: 0022-3573
PB Pharmaceutical Press
DT Journal
LA English
AB Bridelia ferruginea Benth. (Euphorbiaceae) is a subtropical medicinal plant widely used in traditional African medicine against various diseases, including rheumatic pains. Seven of its constituents (3-O-methylquercetin, 3,7,3',4'-tetra-O-methylquercetin (rutisin), myricetin, 3',4',5'-tri-O-methylmyricetin (ferrugin), 3,3',4',5'-tetra-O-methylmyricetin, quercetin 3-O-glucoside, and a biflavanol

gallocatechin-[4'-O-7]-epigallocatechin) have been evaluated in-vitro in the xanthine-xanthine oxidase enzymic system for inhibition of xanthine oxidase and radical scavenging activity. Results indicated that four compds. exhibited, at different levels, xanthine oxidase inhibiting and superoxide scavenging activity at micromolar concns., whereas one compd. showed scavenging activity only. Two of the compds. were inactive in both cases. Study of the structure-activity relation demonstrated that for flavonoids the xanthine oxidase inhibitory activity was reduced by methylation of the hydroxyl functionality at C-3 and in rings A and B. These results may partly explain and support the use of B. ferruginea stem bark for the treatment of rheumatic pains in traditional medicine.

IT **1245-15-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(radical scavenging and xanthine oxidase inhibitory activity of phenolic compds. from Bridelia ferruginea stem bark)

RN 1245-15-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 1992:633705 CAPLUS

DN 117:233705

TI **Pharmaceutical** product for the **therapy** of tumors, particularly ovarian and hemopoietic system tumors, containing quercetin compounds as active substances

IN Mancuso, Salvatore; Folchitto, Giancarlo; Scambia, Giovanni; Benedetti-Pacini, Pier Luigi; Piantelli, Mauro; Ranelletti, Franco Oreste; Cappelli, Arnaldo

PA Romeo, Francesco, Italy; Dalla Costa, Giorgio

SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9213851	A1	19920820	WO 1992-IT7	19920131
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	AU 9212691	A1	19920907	AU 1992-12691	19920131
	EP 570475	A1	19931124	EP 1992-905230	19920131
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, MC, NL, SE				
PRAI	IT 1991-RM85		19910205		
	WO 1992-IT7		19920131		

AB Quercetin compds. such as quercetin Zn and Se complexes, fluorinated and glycosidic quercetins, pentaacetylquercetin, and trimethylquercetin are prepd. for use in tumor **therapy**. E.g., a Zn complex with quercetin was prepd. with the 3',4' hydroxy groups involved in the complex.

IT **572-32-7P 1245-15-4P**, 3,3',4',7-Tetramethylquercetin
RL: PREP (Preparation)
(prepn. of, for tumor **therapy**)
RN 572-32-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1991:101418 CAPLUS
DN 114:101418
TI 4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity
AU De Meyer, Nadine; Haemers, Achiel; Mishra, Lallan; Pandey, Hrishi Kesh; Pieters, L. A. C.; Vanden Berghe, Dirk A.; Vlietinck, Arnold J.
CS Fac. Med., Univ. Antwerp, Antwerp, B-2610, Belg.
SO Journal of Medicinal Chemistry (1991), 34(2), 736-46
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 114:101418
AB 4'-Hydroxy-3-methoxyflavones are natural compds. with known antiviral activities against picornaviruses such as poliomyelitis and rhinoviruses. In order to establish a structure-activity relationship a series of analogs were synthesized, and their antiviral activities and cytotoxicities were compared with those of natural flavones. The 4'-hydroxyl and 3-methoxyl groups, a substituent in the 5-position and a polysubstituted A ring appear to be essential for high activity. The most interesting compd. was 4',7-dihydroxy-3-methoxy-5,6-dimethylflavone (I) possessing in vitro TI99 values (TI = **therapeutic** index) of >1000 and >200 against poliovirus type 1 and rhinovirus type 15, resp. I was also active against other rhinovirus serotypes having ED50 of 0.016-0.5 Mg/mL. Finally in contrast to quercetin it is not mutagenic at .ltoreq.2.5 mg in the Ames test.
IT **1245-15-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(virucidal activity of)
RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1989:470925 CAPLUS
DN 111:70925
TI Effects of flavonoids from oriental drugs on mouse liver sialidase activities
AU Nagai, Takayuki; Yamada, Akishiro; Ohzuka, Yoshio; Miyaichi, Yukinori; Imito, Yoshitaka; Tomimori, Tsuyoshi
CS Kitasato Kenkyusho, Tokyo, Japan
SO Wakan Iyaku Gakkaishi (1988), 5(3), 410-11
CODEN: WIGAES; ISSN: 0289-730X
DT Journal
LA Japanese
AB The inhibitory activity on mouse liver sialidase of 46 flavonoids from oriental drugs was tested; 24 of them had inhibitory activity, with swertisin having the highest activity.
IT **1245-15-4**
RL: BIOL (Biological study)
(of oriental drugs, liver sialidase response to)
RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1988:156489 CAPLUS
DN 108:156489
TI Metal halide modification of plant extracts from zygophyllaceae
IN Jordan, Russell T.
PA Chemex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8706833	A1	19871119	WO 1986-US2543	19861119
	W: AU, BB, DK, JP, KP, KR, NO, SU				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4774229	A	19880927	US 1986-860654	19860507
	AU 8767298	A1	19871201	AU 1987-67298	19861119
	ES 2006474	A6	19890501	ES 1987-1366	19870507
	CA 1303497	A1	19920616	CA 1987-536636	19870507
PRAI	US 1986-860654	A	19860507		
	US 1979-49886	A2	19790619		
	US 1982-365784	A1	19820405		

WO 1986-US2543 A 19861119

AB A mixt. of an ext. from a plant belonging to the zygophyllaceae family contains phenolic compns. and a nonalkali metal salt. It is useful as a **pharmaceutical** agent, e.g. in the treatment of cancer, nonmalignant tumors, osteomyelitis, psoriasis, and warts. Larrea divaricata Was 1st ground to a fine powder of .apprx.1-150 .mu. particle size, and then subjected to extn. with toluene and Et2O. An ointment was made from a dried paste from powd. Larrea divaricata, powd. rose hips, and aq. ZnCl2. Applications to treatment of osteomyelitis and perianal adenomas were successful.

IT **1245-15-4D**, Quercetin 3,7,3',4'-tetramethyl ether, mixts. with metal salts
RL: BIOL (Biological study)
(in treatment of cancer, tumors, osteomyelitis, and skin disorders)

RN 1245-15-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS

AN 1987:428436 CAPLUS

DN 107:28436

TI Photostabilizing sydnone imines

IN Voegele, Dieter; Baumann, Petra; Schoenfinger, Karl

PA Cassella A.-G., Fed. Rep. Ger.

SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 206219	A1	19861230	EP 1986-108241	19860616
	EP 206219	B1	19890906		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
	DE 3522191	A1	19870115	DE 1985-3522191	19850621
	FI 8602475	A	19861222	FI 1986-2475	19860610
	AT 46082	E	19890915	AT 1986-108241	19860616
	JP 62000073	A2	19870106	JP 1986-141532	19860619
	ZA 8604565	A	19870225	ZA 1986-4565	19860619
	HU 40914	A2	19870330	HU 1986-2604	19860620
PRAI	DE 1985-3522191		19850621		
	EP 1986-108241		19860616		

AB The sydnone imines I (R1 = H, alkyl, halo; R2 = H, NO, COR4, SO2R5; R3 = substituted NH2, satd. N-contg. heterocycle; R4 = H, aliph. radical, etc.; R5 = alkyl, aryl, etc.) are photostabilized by the flavonoids II (T1 = H, alkyl, HOCH2CH2, G, etc.; T2 = H, alkyl, alkanoyloxy; T3 = H, alkyl; Y = OH, alkoxy, HOCH2CH2; G = mono- or disaccharide group; Z = III; YZ = IV, V, VI; W1 = H, OH, alkoxy, OG; W2 = H, OH, OG; W3, W4 = H, OH, alkoxy, HOCH2CH2; W5, W6 = H, OH). Thus, Na monorutin sulfate protected 3-(S-dioxotetrahydrothien-3-ylmethylamino)-N-acetylsydmone imine against photodegrdn. in aq. soln. The I-II compns. can be used in drugs.

IT **1245-15-4**
RL: BIOL (Biological study)
(photostabilizer, for sydnone imines)

RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1981:407066 CAPLUS
DN 95:7066
TI Flavone derivatives as antiviral agents, and **pharmaceutical** compositions containing them
IN Ishitsuka, Hideo; Shirai, Haruyoshi; Umeda, Isao; Suhara, Yasuji
PA Hoffmann-La Roche, F., und Co. A.-G., Switz.
SO Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 19081	A1	19801126	EP 1980-101894	19800409
	EP 19081	B1	19841024		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	FI 8001050	A	19801011	FI 1980-1050	19800402
	AU 8057157	A1	19801016	AU 1980-57157	19800403
	AU 538214	B2	19840802		
	IL 59770	A1	19840731	IL 1980-59770	19800404
	US 4352792	A	19821005	US 1980-137637	19800407
	JP 55147272	A2	19801117	JP 1980-45281	19800408
	JP 01018049	B4	19890403		
	NO 8001024	A	19801013	NO 1980-1024	19800409
	DK 8001529	A	19801015	DK 1980-1529	19800409
	BR 8002191	A	19801125	BR 1980-2191	19800409
	ZA 8002139	A	19810429	ZA 1980-2139	19800410
	JP 01117879	A2	19890510	JP 1988-236640	19880922
PRAI	GB 1979-12610		19790410		
	GB 1980-6259		19800225		

AB The flavones I (R = alkyl; R1 = H, alkyl, ester group; R2 = H, alkyl; R3 = H, alkoxy; R4 = H, OH, alkoxy; R5 = H, alkyl, ester group, NH2) were prepd. and tested for virucidal activity (test data tabulated). Thus, II, 4,3-(PhCH2O)(MeO)C6H3CO2Na and the corresponding anhydride were heated at 180-5.degree. under reduced pressure, followed by catalytic hydrogenation to give 90% I (R = R2 = Me, R1 = R3 = R5 = H, R4 = OMe).

IT **572-32-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as virucide)

RN 572-32-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,7-dimethoxy- (9CI) (CA INDEX NAME)



L20 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 1961:131245 CAPLUS
DN 55:131245
OREF 55:24734h-i,24735a-b
TI The flavonoids in Chinese drugs. IV. Chinese mistletoe. 2. The isolation of a flavone arabinoside from Kwang-Chi-Sheng (Loranthus Paraciticus)
AU Ts'eng, Kuang Fang; Ch'en, Chung-Liang
CS Acad. Sinica
SO Yao Hsueh Pao (1957), 5, 317-25
DT Journal
LA Unavailable
AB cf. ibid. 169-77; CA 53, 13509f. Two cryst. compds. were isolated from Chinese mistletoe, known as Kwang-Chi-Sheng, growing in south China. One kg. powd. drug was extd. hot with EtOH 3-4 hrs. 5 times, the alc. ext. was evapd. in vacuo to almost dryness, and the residue was ground with 300 ml. H2O repeatedly and extd. with 300-400 ml. Et2O 10-15 times. After evapn. of the ether, 4 g. crude products, consisting of quercetin 3-arabinoside (I), a powerful diuretic, pale yellow needles, m. 214-15.degree., [.alpha.]16D -157.degree. (c 1.1, EtOH), and quercetin (II), golden yellow needles, m. 310-2.degree. (decompn.), were sepd. by crystn. from MeOH. II was identified by acetylation with Ac2O to the pentaacetyl deriv., m. 195-6.degree., reversible to II on refluxing with alc. KOH, and by exhaustive methylation with CH2N2 in Me2CO to the 3',4',7,3-tetramethyl deriv., m. 156-8.degree.. I was identified by hydrolysis with 5% H2SO4 to give II and L-arabinose, m. 157-60.degree., and exhaustive methylation in MeOH with 20 times the amt. of CH2N2 for 50 hrs. to give colorless needles, m. 223-6.degree.. The latter was hydrolyzed with 5% H2SO4 to 3',4',5,7-tetra-O-methylquercetin, m. 194-5.degree., which yielded on acetylation 3',4',5,7 - tetra - O - methyl - 3 - acetylquercetin, m. 163.degree..
IT **1245-15-4**, Flavone, 5-hydroxy-3,3',4',7-tetramethoxy-
(prepn. of)
RN 1245-15-4 CAPLUS
CN 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,7-dimethoxy- (9CI) (CA INDEX NAME)



=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	62.58	340.18
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.81	-10.41

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:59:34 ON 17 APR 2003

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 552-54-5 REGISTRY
CN 4H-1-Benzopyran-4-one, 3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Flavone, 3,4',5-trihydroxy-3',7-dimethoxy- (8CI)
CN **Rhamnazin (6CI)**
OTHER NAMES:
CN 3',7-Dimethylquercetin
CN 3,4',5-Trihydroxy-3',7-dimethoxyflavone
CN 7,3'-Di-O-methylquercetin
CN 7,3'-Dimethylquercetin
CN C.I. 75700
CN Quercetin 3',7-dimethyl ether
CN Quercetin 7,3'-dimethyl ether
CN Rhamnacine
FS 3D CONCORD
MF C17 H14 O7
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, CSCHEM, IPA, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

127 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
128 REFERENCES IN FILE CAPLUS (1962 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 552-54-5 REGISTRY
CN 4H-1-Benzopyran-4-one, 3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Flavone, 3,4',5-trihydroxy-3',7-dimethoxy- (8CI)
CN **Rhamnazin (6CI)**
OTHER NAMES:
CN 3',7-Dimethylquercetin
CN 3,4',5-Trihydroxy-3',7-dimethoxyflavone
CN 7,3'-Di-O-methylquercetin
CN 7,3'-Dimethylquercetin
CN C.I. 75700
CN Quercetin 3',7-dimethyl ether
CN Quercetin 7,3'-dimethyl ether
CN Rhamnacine
FS 3D CONCORD
MF C17 H14 O7
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CHEMCATS, CSCHEM, IPA, NAPRALERT, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

127 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
128 REFERENCES IN FILE CAPLUS (1962 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

abs for (W)

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2002:384119 CAPLUS
DN 137:62599
TI Flavonols and isoflavones prevent bone loss in the ovariectomized rat: A model for postmenopausal **osteoporosis**
AU Horcajada-Molteni, Marie-Noelle; Coxam, Veronique
CS Unite des Maladies Metaboliques et Micronutriments INRA Theix, Genes-Champanelle, Fr.
SO Nutritional Aspects of Osteoporosis, [International Symposium on the Nutritional Aspects of Osteoporosis], 4th, Lausanne, Switzerland, May 17-20, 2000 (2001), Meeting Date 2000, 325-340. Editor(s): Burckhardt, Peter; Dawson-Hughes, Bess; Heaney, Robert P. Publisher: Academic Press, San Diego, Calif.
CODEN: 69CPIW; ISBN: 0-12-141703-4
DT Conference
LA English
AB Several studies suggest that polyphenols, present in fruits and vegetables, might exert a protective effect against hormone-dependent diseases. The present expt. was carried out to assess the effects of rutin (**quercetin**-3-O-glucose rhamnose, a flavonol) and isoflavones (Soylife, Nederland BV) on bone metab. in ovariectomized rats, an animal model for postmenopausal **osteoporosis**. Thirty rats were thus ovariectomized (OVX), while 10 controls were sham-operated (SH). Among the 30 OVX, 10 were fed for 90 days a synthetic diet (devoid of any vegetal proteins) contg. 0.25% rutin (OVXR); 10 received 0.5% isoflavones (OVXI), while the last 10 and the 10 SH rats were given identical control diets. At necropsy, the decrease in uterine wt. was not different in OVX, OVXR, or OVXI, both treatments being devoid of any uterotrophic effect. Ovariectomy also induced a significant decrease in both total and distal metaphyseal femoral mineral d., which was prevented by rutine or isoflavone consumption. Moreover, femoral failure load, which was not different in OVX and SH, was even higher in OVXR. However, isoflavones did not elicit any improvement of this parameter. On the other hand, on day 90, urinary deoxypyridinoline excretion (a marker for bone resorption)

was higher in OVX than in OVXR, OVXI, or SH. Simultaneously, plasma osteocalcin concn. (a marker for osteoblastic activity) was higher in OVX, OVXR, or OVXI than in SH. These results indicate that rutine (and/or its metabolites) and isoflavones, which appeared to be devoid of any uterotrophic activity, inhibit ovariectomy-induced trabecular bone loss in rats by slowing bone turnover, but mainly by decreasing resorption. Flavonols (rutine) even improved bone quality, as shown by bone strength assessment. In conclusion, the current dietary recommendations that emphasize an increase in the proportion and amt. of fruits and vegetables that should be consumed apply to skeletal diseases, as well. (c) 2001 Academic Press.

IT **153-18-4**, Rutin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dietary fruit and vegetables effect on bone metab. in relation to osteoporosis)

RN 153-18-4 CAPLUS

CN 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT